

Engineered T cells: the promise and challenges of cancer immunotherapy

Nature Reviews Cancer

16, 566-581

DOI: [10.1038/nrc.2016.97](https://doi.org/10.1038/nrc.2016.97)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART). <i>Translational Lung Cancer Research</i> , 2007, 6, 159-168.	1.3	32
3	Diacylglycerol Kinases in T Cell Tolerance and Effector Function. <i>Frontiers in Cell and Developmental Biology</i> , 2016, 4, 130.	1.8	22
4	Cytotoxic CD4 T Cells: Differentiation, Function, and Application to Dengue Virus Infection. <i>Frontiers in Immunology</i> , 2016, 7, 531.	2.2	74
6	NK cells converge lytic granules to promote cytotoxicity and prevent bystander killing. <i>Journal of Cell Biology</i> , 2016, 215, 875-889.	2.3	87
7	Engineering HIV-Specific Immunity with Chimeric Antigen Receptors. <i>AIDS Patient Care and STDs</i> , 2016, 30, 556-561.	1.1	14
8	Immuno-oncology: Allying forces of radio- and immuno-therapy to enhance cancer cell killing. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 108, 97-108.	2.0	25
9	In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy. <i>Nature Biomedical Engineering</i> , 2017, 1, .	11.6	390
10	The revival of cancer vaccines – The eminent need to activate humoral immunity. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1112-1114.	1.4	16
11	Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. <i>Cell</i> , 2017, 168, 707-723.	13.5	3,483
12	The CD47-SIRP α signaling axis as an innate immune checkpoint in cancer. <i>Immunological Reviews</i> , 2017, 276, 145-164.	2.8	410
13	The best spot to park a CAR. <i>Nature Biotechnology</i> , 2017, 35, 341-341.	9.4	0
14	Harnessing Advances in T Regulatory Cell Biology for Cellular Therapy in Transplantation. <i>Transplantation</i> , 2017, 101, 2277-2287.	0.5	37
15	T cell receptor α chain repertoire analysis reveals the association between neoantigens and tumour-infiltrating lymphocytes in multifocal papillary thyroid carcinoma. <i>International Journal of Cancer</i> , 2017, 141, 377-382.	2.3	13
16	Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies. <i>Cancer Journal (Sudbury)</i> , 2017, 13, 1-7.	1.0	0
17	Single Cell Analysis. <i>Series in Bioengineering</i> , 2017, .	0.3	1
18	Sensing Bad: Are Co-stimulatory CAR-Expressing T Cells Safer?. <i>Molecular Therapy</i> , 2017, 25, 1064-1066.	3.7	2
19	Long-Term Efficacy and Safety of Insulin and Glucokinase Gene Therapy for Diabetes: 8-Year Follow-Up in Dogs. <i>Molecular Therapy - Methods and Clinical Development</i> , 2017, 6, 1-7.	1.8	23
20	Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment. <i>Protein and Cell</i> , 2017, 8, 896-925.	4.8	59

#	ARTICLE	IF	CITATIONS
21	Transcriptional and epigenetic regulation of T cell hyporesponsiveness. <i>Journal of Leukocyte Biology</i> , 2017, 102, 601-615.	1.5	39
22	Cells as advanced therapeutics: State-of-the-art, challenges, and opportunities in large scale biomanufacturing of high-quality cells for adoptive immunotherapies. <i>Advanced Drug Delivery Reviews</i> , 2017, 114, 222-239.	6.6	52
23	Cell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus Reservoir. <i>Journal of Infectious Diseases</i> , 2017, 215, S160-S171.	1.9	24
24	The Individual and Population Genetics of Antibody Immunity. <i>Trends in Immunology</i> , 2017, 38, 459-470.	2.9	134
25	Delivering safer immunotherapies for cancer. <i>Advanced Drug Delivery Reviews</i> , 2017, 114, 79-101.	6.6	233
26	Engineering challenges for brain tumor immunotherapy. <i>Advanced Drug Delivery Reviews</i> , 2017, 114, 19-32.	6.6	62
27	The frequency of neoantigens per somatic mutation rather than overall mutational load or number of predicted neoantigens per se is a prognostic factor in ovarian clear cell carcinoma. <i>Oncot Immunology</i> , 2017, 6, e1338996.	2.1	22
28	3D printed lattices as an activation and expansion platform for T cell therapy. <i>Biomaterials</i> , 2017, 140, 58-68.	5.7	32
29	Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook. <i>Advanced Materials</i> , 2017, 29, 1606036.	11.1	220
30	Hemophilia A inhibitor treatment: the promise of engineered T-cell therapy. <i>Translational Research</i> , 2017, 187, 44-52.	2.2	16
31	Beyond checkpoint inhibition – Immunotherapeutical strategies in combination with radiation. <i>Clinical and Translational Radiation Oncology</i> , 2017, 2, 29-35.	0.9	27
32	T-cell target antigens across major gynecologic cancers. <i>Gynecologic Oncology</i> , 2017, 145, 426-435.	0.6	24
33	Prospects for combining targeted and conventional cancer therapy with immunotherapy. <i>Nature Reviews Cancer</i> , 2017, 17, 286-301.	12.8	742
34	How do i participate in T cell immunotherapy?. <i>Transfusion</i> , 2017, 57, 1115-1121.	0.8	3
35	Creating a Homeodomain with High Stability and DNA Binding Affinity by Sequence Averaging. <i>Journal of the American Chemical Society</i> , 2017, 139, 5051-5060.	6.6	24
36	Homology-Directed Recombination for Enhanced Engineering of Chimeric Antigen Receptor T Cells. <i>Molecular Therapy - Methods and Clinical Development</i> , 2017, 4, 192-203.	1.8	53
37	Chimeric antigen receptor T cells: a novel therapy for solid tumors. <i>Journal of Hematology and Oncology</i> , 2017, 10, 78.	6.9	232
38	Editing the genome of hiPSC with CRISPR/Cas9: disease models. <i>Mammalian Genome</i> , 2017, 28, 348-364.	1.0	72

#	ARTICLE	IF	CITATIONS
39	Driving gene-engineered T cell immunotherapy of cancer. <i>Cell Research</i> , 2017, 27, 38-58.	5.7	232
40	Synthetic Biologyâ€”The Synthesis of Biology. <i>Angewandte Chemie - International Edition</i> , 2017, 56, 6396-6419.	7.2	141
41	Synthetische Biologie â€“ die Synthese der Biologie. <i>Angewandte Chemie</i> , 2017, 129, 6494-6519.	1.6	11
42	Rewiring human cellular inputâ€”output using modular extracellular sensors. <i>Nature Chemical Biology</i> , 2017, 13, 202-209.	3.9	124
43	c-MPL provides tumor-targeted T-cell receptor-transgenic T cells with costimulation and cytokine signals. <i>Blood</i> , 2017, 130, 2739-2749.	0.6	8
44	Cancer Immunotherapy Getting Brainy: Visualizing the Distinctive CNS Metastatic Niche to Illuminate Therapeutic Resistance. <i>Drug Resistance Updates</i> , 2017, 33-35, 23-35.	6.5	16
45	Synthetic biology â€“ Engineering cell-based biomedical devices. <i>Current Opinion in Biomedical Engineering</i> , 2017, 4, 50-56.	1.8	7
46	NK Cells and Î³Î”T Cells for Relapse Protection after Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Current Stem Cell Reports</i> , 2017, 3, 301-311.	0.7	13
47	CARs on a highway with roadblocks. <i>Oncot Immunology</i> , 2017, 6, e1388486.	2.1	7
48	Genome and Epigenome Editing to Treat Disorders of the Hematopoietic System. <i>Human Gene Therapy</i> , 2017, 28, 1105-1115.	1.4	20
49	Inducible Enhancement of T Cell Function and Anti-tumor Activity after Adoptive Transfer. <i>Molecular Therapy</i> , 2017, 25, 1995-1996.	3.7	1
50	Combination Cancer Therapy Using Chimeric Antigen Receptor-Engineered Natural Killer Cells as Drug Carriers. <i>Molecular Therapy</i> , 2017, 25, 2607-2619.	3.7	72
51	Multiplexing Engineered Receptors for Multiparametric Evaluation of Environmental Ligands. <i>ACS Synthetic Biology</i> , 2017, 6, 2042-2055.	1.9	30
52	Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. <i>Oncot Immunology</i> , 2017, 6, e1371896.	2.1	36
53	Biomimetic Magnetosomes as Versatile Artificial Antigen-Presenting Cells to Potentiate T-Cell-Based Anticancer Therapy. <i>ACS Nano</i> , 2017, 11, 10724-10732.	7.3	150
54	Bacterial outer membrane vesicles suppress tumor by interferon-Î³-mediated antitumor response. <i>Nature Communications</i> , 2017, 8, 626.	5.8	329
55	Application of chimeric antigen receptor-engineered T cells in ovarian cancer therapy. <i>Immunotherapy</i> , 2017, 9, 851-861.	1.0	8
56	Two is better than one: advances in pathogen-boosted immunotherapy and adoptive T-cell therapy. <i>Immunotherapy</i> , 2017, 9, 837-849.	1.0	1

#	ARTICLE	IF	CITATIONS
57	Mitochondrial Priming by CD28. <i>Cell</i> , 2017, 171, 385-397.e11.	13.5	212
58	Engineering Synthetic Signaling Pathways with Programmable dCas9-Based Chimeric Receptors. <i>Cell Reports</i> , 2017, 20, 2639-2653.	2.9	64
59	Culturing CTLs under Hypoxic Conditions Enhances Their Cytolysis and Improves Their Anti-tumor Function. <i>Cell Reports</i> , 2017, 20, 2547-2555.	2.9	118
60	Acute myeloid leukemia with mutated nucleophosmin 1: an immunogenic acute myeloid leukemia subtype and potential candidate for immune checkpoint inhibition. <i>Haematologica</i> , 2017, 102, e499-e501.	1.7	26
61	Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers. <i>Nature Communications</i> , 2017, 8, 389.	5.8	133
62	Advances in cancer stem cell targeting: How to strike the evil at its root. <i>Advanced Drug Delivery Reviews</i> , 2017, 120, 89-107.	6.6	58
63	Treating breast cancer with cell-based approaches: an overview. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1255-1264.	1.4	4
64	Reprogramming cellular functions with engineered membrane proteins. <i>Current Opinion in Biotechnology</i> , 2017, 47, 92-101.	3.3	19
65	A Comparative Study of Clinical Intervention and Interventional Photothermal Therapy for Pancreatic Cancer. <i>Advanced Materials</i> , 2017, 29, 1700448.	11.1	86
66	Reconstructing the immune system with lentiviral vectors. <i>Virus Genes</i> , 2017, 53, 723-732.	0.7	20
67	Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2. <i>Structure</i> , 2017, 25, 1163-1174.	1.6	253
68	New approaches for the enhancement of chimeric antigen receptors for the treatment of HIV. <i>Translational Research</i> , 2017, 187, 83-92.	2.2	13
69	Clinical development of CAR T cells—challenges and opportunities in translating innovative treatment concepts. <i>EMBO Molecular Medicine</i> , 2017, 9, 1183-1197.	3.3	397
70	Trial Watch: Adoptively transferred cells for anticancer immunotherapy. <i>Oncolimmunology</i> , 2017, 6, e1363139.	2.1	60
71	A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma. <i>Molecular Therapy</i> , 2017, 25, 2299-2308.	3.7	21
73	Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types. <i>BMJ Open</i> , 2017, 7, e017075.	0.8	43
74	Young donor white blood cell immunotherapy induces extensive tumor necrosis in advanced-stage solid tumors. <i>Heliyon</i> , 2017, 3, e00438.	1.4	9
75	Heating up cancer vaccines. <i>Science Immunology</i> , 2017, 2, .	5.6	2

#	ARTICLE	IF	CITATIONS
76	Tuning up T-cell receptors. <i>Nature Biotechnology</i> , 2017, 35, 1145-1146.	9.4	1
77	Harnessing designed nanoparticles: Current strategies and future perspectives in cancer immunotherapy. <i>Nano Today</i> , 2017, 17, 23-37.	6.2	69
78	Accelerating Patients' Access to Advanced Therapies in the EU. <i>Molecular Therapy - Methods and Clinical Development</i> , 2017, 7, 15-19.	1.8	19
79	Fight fire with fire: Gene therapy strategies to cure HIV. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 747-758.	2.0	13
80	Manufacturing Cell Therapies Using Engineered Biomaterials. <i>Trends in Biotechnology</i> , 2017, 35, 971-982.	4.9	35
81	Targeting EGFRvIII for glioblastoma multiforme. <i>Cancer Letters</i> , 2017, 403, 224-230.	3.2	48
82	Ionic CD3 α -Lck interaction regulates the initiation of T-cell receptor signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E5891-E5899.	3.3	70
83	Chimeric antigen receptor T-cells for B-cell malignancies. <i>Translational Research</i> , 2017, 187, 59-82.	2.2	22
84	Molecular imaging biomarkers for cell-based immunotherapies. <i>Journal of Translational Medicine</i> , 2017, 15, 140.	1.8	11
85	Mitochondrial control of immunity: beyond ATP. <i>Nature Reviews Immunology</i> , 2017, 17, 608-620.	10.6	306
86	Genome Editing Techniques and Their Therapeutic Applications. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 42-51.	2.3	18
87	Presence of an Immune System Increases Anti-Tumor Effect of Ag Nanoparticle Treated Mice. <i>Advanced Healthcare Materials</i> , 2017, 6, 1601099.	3.9	22
88	Application of Nanocomposites in Cancer Immunotherapy. <i>Nano LIFE</i> , 2017, 07, 1750008.	0.6	2
89	Informatics for cancer immunotherapy. <i>Annals of Oncology</i> , 2017, 28, xii56-xii73.	0.6	19
90	New insight into cancer immunotherapy. <i>Allergologia Et Immunopathologia</i> , 2017, 45, 50-55.	1.0	3
91	The revolution of lung cancer treatment: from vaccines, to immune checkpoint inhibitors, to chimeric antigen receptor T therapy. <i>Biotarget</i> , 0, 1, 7-7.	0.5	11
92	DGK- β : A Checkpoint in Cancer-Mediated Immuno-Inhibition and Target for Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2017, 5, 16.	1.8	27
93	Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1201.	1.8	14

#	ARTICLE	IF	CITATIONS
94	Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel. <i>Frontiers in Immunology</i> , 2017, 8, 267.	2.2	61
95	Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity. <i>Frontiers in Immunology</i> , 2017, 8, 533.	2.2	232
96	Multifaceted Role of Neuropilins in the Immune System: Potential Targets for Immunotherapy. <i>Frontiers in Immunology</i> , 2017, 8, 1228.	2.2	165
97	Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma. <i>Frontiers in Immunology</i> , 2017, 8, 1617.	2.2	43
98	Harnessing the Power of Invariant Natural Killer T Cells in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2017, 8, 1829.	2.2	49
99	Bioengineering of Artificial Antigen Presenting Cells and Lymphoid Organs. <i>Theranostics</i> , 2017, 7, 3504-3516.	4.6	54
100	Amatuximab and novel agents targeting mesothelin for solid tumors. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5337-5353.	1.0	28
101	Antibody-Recruiting Small Molecules: Synthetic Constructs as Immunotherapeutics. <i>Annual Reports in Medicinal Chemistry</i> , 2017, 50, 481-518.	0.5	3
102	Prospects for combined use of oncolytic viruses and CAR T-cells. , 2017, 5, 90.		84
103	Immune Cells As Targets and Tools For Cancer Therapy. <i>Immunotherapy (Los Angeles, Calif)</i> , 2017, 03, .	0.1	0
104	Tumor location impacts immune response in mouse models of colon cancer. <i>Oncotarget</i> , 2017, 8, 54775-54787.	0.8	75
105	Driving T-cell immunotherapy to solid tumors. <i>Nature Biotechnology</i> , 2018, 36, 215-219.	9.4	117
106	Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 325-340.	12.5	1,192
107	Powered and controlled T-cell production. <i>Nature Biomedical Engineering</i> , 2018, 2, 148-150.	11.6	5
108	Metformin blocks myeloid-derived suppressor cell accumulation through AMPK-DACH1-CXCL1 axis. <i>OncImmunology</i> , 2018, 7, e1442167.	2.1	67
109	T-cell Immunotherapies and the Role of Nonclinical Assessment: The Balance between Efficacy and Pathology. <i>Toxicologic Pathology</i> , 2018, 46, 131-146.	0.9	12
110	Optimized DNA electroporation for primary human T cell engineering. <i>BMC Biotechnology</i> , 2018, 18, 4.	1.7	63
111	Engineering chimeric antigen receptor-T cells for cancer treatment. <i>Molecular Cancer</i> , 2018, 17, 32.	7.9	57

#	ARTICLE	IF	CITATIONS
112	Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward. <i>Journal of Hematology and Oncology</i> , 2018, 11, 22.	6.9	176
113	Increased risk of hematologic malignancies in primary immunodeficiency disorders: opportunities for immunotherapy. <i>Clinical Immunology</i> , 2018, 190, 22-31.	1.4	27
114	The Pharmacology of T Cell Therapies. <i>Molecular Therapy - Methods and Clinical Development</i> , 2018, 8, 210-221.	1.8	78
115	CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2018, 78, 145-150.	0.8	39
116	TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor <i>CD274</i> (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas. <i>Oncolimmunology</i> , 2018, 7, e1442999.	2.1	53
117	Mitochondrial Morphological and Functional Reprogramming Following <i>CD137</i> (4-1BB) Costimulation. <i>Cancer Immunology Research</i> , 2018, 6, 798-811.	1.6	62
118	Oncolytic viruses as engineering platforms for combination immunotherapy. <i>Nature Reviews Cancer</i> , 2018, 18, 419-432.	12.8	288
119	Celyad's novel CAR T-cell therapy for solid malignancies. <i>Current Research in Translational Medicine</i> , 2018, 66, 53-56.	1.2	21
120	The Cish SH2 domain is essential for <i>PLC-β1</i> regulation in TCR stimulated CD8+ T cells. <i>Scientific Reports</i> , 2018, 8, 5336.	1.6	32
121	Transposon-modified antigen-specific T lymphocytes for sustained therapeutic protein delivery in vivo. <i>Nature Communications</i> , 2018, 9, 1325.	5.8	16
122	Current state of immunotherapy for glioblastoma. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 422-442.	12.5	873
123	Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma. <i>Current Research in Translational Medicine</i> , 2018, 66, 43-49.	1.2	45
124	<i>PD-1</i> Blockade Cellular Vesicles for Cancer Immunotherapy. <i>Advanced Materials</i> , 2018, 30, e1707112.	11.1	196
125	Continuous production process of retroviral vector for adoptive T- cell therapy. <i>Biochemical Engineering Journal</i> , 2018, 132, 145-151.	1.8	1
126	A guide to manufacturing CAR T cell therapies. <i>Current Opinion in Biotechnology</i> , 2018, 53, 164-181.	3.3	262
127	Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. <i>Oncolimmunology</i> , 2018, 7, e1433982.	2.1	38
128	Polyvalent Display of Biomolecules on Live Cells. <i>Angewandte Chemie</i> , 2018, 130, 6916-6920.	1.6	11
129	Cancer immunotherapy beyond immune checkpoint inhibitors. <i>Journal of Hematology and Oncology</i> , 2018, 11, 8.	6.9	174

#	ARTICLE	IF	CITATIONS
130	Adaptive immune cells are necessary for the enhanced therapeutic effect of sorafenib-loaded nanoparticles. <i>Biomaterials Science</i> , 2018, 6, 893-900.	2.6	19
131	Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma. <i>Onc Immunology</i> , 2018, 7, e1434464.	2.1	69
132	Highly Efficient and Versatile Plasmid-Based Gene Editing in Primary T Cells. <i>Journal of Immunology</i> , 2018, 200, 2489-2501.	0.4	28
133	Polyvalent Display of Biomolecules on Live Cells. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 6800-6804.	7.2	54
134	Leukocyte-derived biomimetic nanoparticulate drug delivery systems for cancer therapy. <i>Acta Pharmaceutica Sinica B</i> , 2018, 8, 4-13.	5.7	65
135	Mechanogenetics for the remote and noninvasive control of cancer immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 992-997.	3.3	181
136	Enhanced Immunotherapy Based on Photodynamic Therapy for Both Primary and Lung Metastasis Tumor Eradication. <i>ACS Nano</i> , 2018, 12, 1978-1989.	7.3	250
138	Eomesodermin Increases Survival and IL-2 Responsiveness of Tumor-specific CD8+ T Cells in an Adoptive Transfer Model of Cancer Immunotherapy. <i>Journal of Immunotherapy</i> , 2018, 41, 53-63.	1.2	4
139	Multifunctional Microwell Arrays for Single Cell Level Functional Analysis of Lymphocytes. <i>Bioconjugate Chemistry</i> , 2018, 29, 672-679.	1.8	18
140	A tritherapy combination of inactivated allogeneic leukocytes infusion and cell vaccine with cyclophosphamide in a sequential regimen enhances antitumor immunity. <i>Journal of the Chinese Medical Association</i> , 2018, 81, 316-323.	0.6	3
141	Immunoengineering with biomaterials for enhanced cancer immunotherapy. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2018, 10, e1506.	3.3	33
142	Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells. <i>Nature Biotechnology</i> , 2018, 36, 160-169.	9.4	271
143	Blockade of BAFF Receptor BR3 on T Cells Enhances Their Activation and Cytotoxicity. <i>Journal of Immunotherapy</i> , 2018, 41, 213-223.	1.2	7
144	CAR-T Cells Surface-Engineered with Drug-Encapsulated Nanoparticles Can Ameliorate Intratumoral T-cell Hypofunction. <i>Cancer Immunology Research</i> , 2018, 6, 812-824.	1.6	100
145	Shock wave-induced permeabilization of mammalian cells. <i>Physics of Life Reviews</i> , 2018, 26-27, 1-38.	1.5	24
146	Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide. <i>Journal of Hematology and Oncology</i> , 2018, 11, 44.	6.9	32
147	miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy. <i>Journal of Hematology and Oncology</i> , 2018, 11, 58.	6.9	98
148	Correlates of immune and clinical activity of novel cancer vaccines. <i>Seminars in Immunology</i> , 2018, 39, 119-136.	2.7	54

#	ARTICLE	IF	CITATIONS
149	PD-L1-independent Mechanisms Control the Resistance of Melanoma to CD4+ T Cell Adoptive Immunotherapy. <i>Journal of Immunology</i> , 2018, 200, 3304-3311.	0.4	6
150	Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy. <i>Gene Therapy</i> , 2018, 25, 198-204.	2.3	8
151	Paramunity-inducing Factors (PINDs) in dendritic cell (DC) cultures lead to impaired antileukemic functionality of DC-stimulated T-cells. <i>Cellular Immunology</i> , 2018, 328, 33-48.	1.4	2
152	Efficient Non-Viral T-Cell Engineering by Sleeping Beauty Minicircles Diminishing DNA Toxicity and miRNAs Silencing the Endogenous T-Cell Receptors. <i>Human Gene Therapy</i> , 2018, 29, 569-584.	1.4	35
153	Engineering Reversible Cell-Cell Interactions with Lipid Anchored Prosthetic Receptors. <i>Bioconjugate Chemistry</i> , 2018, 29, 1291-1301.	1.8	19
154	In Vitro Modeling of Tumor-Immune System Interaction. <i>ACS Biomaterials Science and Engineering</i> , 2018, 4, 314-323.	2.6	21
155	How immunotherapies are targeting the glioblastoma immune environment. <i>Journal of Clinical Neuroscience</i> , 2018, 47, 20-27.	0.8	8
156	STCRDab: the structural T-cell receptor database. <i>Nucleic Acids Research</i> , 2018, 46, D406-D412.	6.5	69
157	PD-1 pathway and its clinical application: A 20 year journey after discovery of the complete human PD-1 gene. <i>Gene</i> , 2018, 638, 20-25.	1.0	87
158	Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4-1BB). <i>Oncotmunology</i> , 2018, 7, e1368605.	2.1	7
159	Treating hematological malignancies with cell therapy: where are we now?. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 65-75.	1.4	17
160	Primary T cells for mRNA-mediated immunotoxin delivery. <i>Gene Therapy</i> , 2018, 25, 47-53.	2.3	5
161	Targets for immunotherapy of liver cancer. <i>Journal of Hepatology</i> , 2018, 68, 157-166.	1.8	129
162	Towards personalized, tumour-specific, therapeutic vaccines for cancer. <i>Nature Reviews Immunology</i> , 2018, 18, 168-182.	10.6	736
163	Cellular Bioparticulates with Therapeutics for Cancer Immunotherapy. <i>Bioconjugate Chemistry</i> , 2018, 29, 702-708.	1.8	17
164	Metallic nanoparticles for cancer immunotherapy. <i>Materials Today</i> , 2018, 21, 673-685.	8.3	164
166	Cellular Therapy. <i>Current Cancer Research</i> , 2018, , 133-184.	0.2	0
167	CAR T-Cell Therapies in Glioblastoma: A First Look. <i>Clinical Cancer Research</i> , 2018, 24, 535-540.	3.2	103

#	ARTICLE	IF	CITATIONS
168	In-vitro blockade of the CD4 receptor co-signal in antigen-specific T-cell stimulation cultures induces the outgrowth of potent CD4 independent T-cell effectors. <i>Journal of Immunological Methods</i> , 2018, 454, 80-85.	0.6	1
169	Targeting and suppression of HER3-positive breast cancer by T lymphocytes expressing a heregulin chimeric antigen receptor. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 393-401.	2.0	15
170	CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell-Associated Relevant Genes. <i>Cancer Immunology Research</i> , 2018, 6, 69-78.	1.6	34
171	A Jurkat 76 based triple parameter reporter system to evaluate TCR functions and adoptive T cell strategies. <i>Oncotarget</i> , 2018, 9, 17608-17619.	0.8	55
173	Publications Are Not the Finish Line: Focusing on Societal Rather Than Publication Impact. <i>Frontiers in Medicine</i> , 2018, 5, 314.	1.2	7
174	Rational Design of Nanoparticles with Deep Tumor Penetration for Effective Treatment of Tumor Metastasis. <i>Advanced Functional Materials</i> , 2018, 28, 1801840.	7.8	112
175	Vaccines Developed for Cancer Immunotherapy. , 2018, , .		0
177	Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy. <i>Science China Life Sciences</i> , 2018, 61, 1320-1332.	2.3	11
178	Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance. <i>BMC Cancer</i> , 2018, 18, 1082.	1.1	42
179	PD-1/PD-L1 pathway and angiogenesis dual recognizable nanoparticles for enhancing chemotherapy of malignant cancer. <i>Drug Delivery</i> , 2018, 25, 1746-1755.	2.5	25
180	How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation. <i>Nature Biomedical Engineering</i> , 2018, 2, 797-809.	11.6	99
181	Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors <i>in vivo</i> . <i>Experimental and Therapeutic Medicine</i> , 2019, 17, 739-747.	0.8	21
182	Overcoming Target Driven Fratricide for T Cell Therapy. <i>Frontiers in Immunology</i> , 2018, 9, 2940.	2.2	26
183	CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success. <i>Frontiers in Immunology</i> , 2018, 9, 2740.	2.2	58
184	Flow cytometric assays for identity, safety and potency of cellular therapies. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 725-735.	0.7	13
185	Integrating Immunology and Microfluidics for Single Immune Cell Analysis. <i>Frontiers in Immunology</i> , 2018, 9, 2373.	2.2	54
186	Chimeric antigen receptor modified T cells for cancer treatment. <i>Chronic Diseases and Translational Medicine</i> , 2018, 4, 225-243.	0.9	10
187	Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in Rhabdomyosarcoma. <i>Molecules</i> , 2018, 23, 2798.	1.7	45

#	ARTICLE	IF	CITATIONS
188	Non-Viral Transfection of Human T Lymphocytes. <i>Processes</i> , 2018, 6, 188.	1.3	18
189	Synthetic immunology: T-cell engineering and adoptive immunotherapy. <i>Synthetic and Systems Biotechnology</i> , 2018, 3, 179-185.	1.8	23
190	Blossom of CRISPR technologies and applications in disease treatment. <i>Synthetic and Systems Biotechnology</i> , 2018, 3, 217-228.	1.8	20
191	Fluorine-19 MRI for detection and quantification of immune cell therapy for cancer. , 2018, 6, 105.		75
193	Porous and responsive hydrogels for cell therapy. <i>Current Opinion in Colloid and Interface Science</i> , 2018, 38, 135-157.	3.4	35
194	Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity. <i>JCI Insight</i> , 2018, 3, .	2.3	150
196	<scp>NKT</scp> cells â€” New players in <scp>CAR</scp> cell immunotherapy?. <i>European Journal of Haematology</i> , 2018, 101, 750-757.	1.1	33
197	Trial watch: Peptide-based vaccines in anticancer therapy. <i>OncImmunology</i> , 2018, 7, e1511506.	2.1	121
198	Computational Model of Chimeric Antigen Receptors Explains Site-Specific Phosphorylation Kinetics. <i>Biophysical Journal</i> , 2018, 115, 1116-1129.	0.2	35
199	Effects of CSF1R-targeted chimeric antigen receptor-modified NK92MI & T cells on tumor-associated macrophages. <i>Immunotherapy</i> , 2018, 10, 935-949.	1.0	30
200	Chimeric antigen receptor T-cell therapy hits the market. <i>Immunotherapy</i> , 2018, 10, 911-912.	1.0	2
201	Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3KÎ inhibitors and VIP antagonists. <i>Blood Advances</i> , 2018, 2, 210-223.	2.5	87
202	Biocompatible coupling of therapeutic fusion proteins to human erythrocytes. <i>Blood Advances</i> , 2018, 2, 165-176.	2.5	42
203	Sequential allogeneic and autologous CAR-Tâ€™ cell therapy to treat an immune-compromised leukemic patient. <i>Blood Advances</i> , 2018, 2, 1691-1695.	2.5	31
204	Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E5467-E5476.	3.3	60
205	The role of the common gamma-chain family cytokines in Î³ T cell-based anti-cancer immunotherapy. <i>Cytokine and Growth Factor Reviews</i> , 2018, 41, 54-64.	3.2	16
206	Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. <i>Trends in Immunology</i> , 2018, 39, 624-631.	2.9	153
207	The current status of immunotherapy for cervical cancer. <i>Reports of Practical Oncology and Radiotherapy</i> , 2018, 23, 580-588.	0.3	39

#	ARTICLE	IF	CITATIONS
209	Designing cell function: assembly of synthetic gene circuits for cell biology applications. Nature Reviews Molecular Cell Biology, 2018, 19, 507-525.	16.1	205
210	Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy – Moving Target for Industry?. Pharmaceutical Research, 2018, 35, 152.	1.7	77
211	The potential of nanoparticle vaccines as a treatment for cancer. Molecular Immunology, 2018, 98, 2-7.	1.0	27
212	Artificial 3D Culture Systems for T Cell Expansion. ACS Omega, 2018, 3, 5273-5280.	1.6	28
213	Emerging functional markers for cancer stem cell-based therapies: Understanding signaling networks for targeting metastasis. Seminars in Cancer Biology, 2018, 53, 90-109.	4.3	62
214	Generation and application of human induced stem cell memory T cells for adoptive immunotherapy. Cancer Science, 2018, 109, 2130-2140.	1.7	33
215	Immunoglobulin gene analysis as a tool for investigating human immune responses. Immunological Reviews, 2018, 284, 132-147.	2.8	33
216	Growth Factor Signaling Pathways and Targeted Therapy. , 2018, , 305-322.		0
217	Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. Cell Stem Cell, 2018, 23, 181-192.e5.	5.2	634
218	Chimeric antigen receptors that trigger phagocytosis. ELife, 2018, 7, .	2.8	210
219	Cytokine release syndrome. , 2018, 6, 56.		1,055
220	BioBits – Explorer: A modular synthetic biology education kit. Science Advances, 2018, 4, eaat5105.	4.7	113
221	Immunotherapy for Gastric Cancer: Time for a Personalized Approach?. International Journal of Molecular Sciences, 2018, 19, 1602.	1.8	48
222	The Effect of Immunosuppressive Drugs on MDSCs in Transplantation. Journal of Immunology Research, 2018, 2018, 1-16.	0.9	18
223	Toward Biomaterials for Enhancing Immune Checkpoint Blockade Therapy. Advanced Functional Materials, 2018, 28, 1802540.	7.8	92
224	CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies. Frontiers in Immunology, 2018, 9, 1740.	2.2	155
225	Immunotherapy in Glioblastoma. World Neurosurgery, 2018, 116, 518-528.	0.7	31
226	Interferon gene therapy reprograms the leukemia microenvironment inducing protective immunity to multiple tumor antigens. Nature Communications, 2018, 9, 2896.	5.8	39

#	ARTICLE	IF	CITATIONS
227	Construction of an anti- ϵ -programmed death- ϵ ligand 1 chimeric antigen receptor and determination of its antitumor function with transduced cells. <i>Oncology Letters</i> , 2018, 16, 157-166.	0.8	9
228	CAR T cells for infection, autoimmunity and allotransplantation. <i>Nature Reviews Immunology</i> , 2018, 18, 605-616.	10.6	173
229	Intracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts. <i>Chemical Reviews</i> , 2018, 118, 7409-7531.	23.0	490
230	The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity. <i>Nature Communications</i> , 2018, 9, 3049.	5.8	82
231	Embryonic Fibroblasts Promote Antitumor Cytotoxic Effects of CD8+ T Cells. <i>Frontiers in Immunology</i> , 2018, 9, 685.	2.2	3
232	The Use of the Humanized Mouse Model in Gene Therapy and Immunotherapy for HIV and Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 746.	2.2	31
233	Expansion and Antitumor Cytotoxicity of T-Cells Are Augmented by Substrate-Bound CCL21 and Intercellular Adhesion Molecule 1. <i>Frontiers in Immunology</i> , 2018, 9, 1303.	2.2	18
234	Influence of various medium environment to in vitro human T cell culture. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2018, 54, 559-566.	0.7	24
235	Versatile CAR T-cells for cancer immunotherapy. <i>Wspolczesna Onkologia</i> , 2018, 2018, 73-80.	0.7	13
236	IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer. <i>Cancer Research</i> , 2018, 78, 5243-5258.	0.4	119
237	The research significance of concomitant use of CAR-CD138-NK and CAR-CD19-NK to target multiple myelomas. <i>European Journal of Inflammation</i> , 2018, 16, 205873921878896.	0.2	7
238	Biomimetic Tissue Engineering: Tuning the Immune and Inflammatory Response to Implantable Biomaterials. <i>Advanced Healthcare Materials</i> , 2018, 7, e1800490.	3.9	84
239	HDACi Delivery Reprograms Tumor-Infiltrating Myeloid Cells to Eliminate Antigen-Loss Variants. <i>Cell Reports</i> , 2018, 24, 642-654.	2.9	19
240	Reducing <i>Ex Vivo</i> Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells. <i>Cancer Immunology Research</i> , 2018, 6, 1100-1109.	1.6	189
241	Safety Strategies of Genetically Engineered T Cells in Cancer Immunotherapy. <i>Current Pharmaceutical Design</i> , 2018, 24, 78-83.	0.9	7
242	CIMT 2018: Pushing frontiers in cancer immunotherapy – Report on the 16th Annual Meeting of the Association for Cancer Immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2864-2873.	1.4	1
243	Therapeutic applications of the NCPG™ family of viral 2As. <i>Reviews in Medical Virology</i> , 2018, 28, e2001.	3.9	13
244	A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens. <i>Blood</i> , 2018, 132, 1911-1921.	0.6	44

#	ARTICLE	IF	CITATIONS
245	Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy. <i>Journal of Hematology and Oncology</i> , 2018, 11, 102.	6.9	63
246	Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells. <i>Frontiers in Immunology</i> , 2018, 9, 1717.	2.2	51
247	A method for expansion of T cells from cynomolgus monkey (<i>Macaca fascicularis</i>). <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2018, 54, 549-554.	0.7	0
248	CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30+ and CD30 ^{hi} Embryonal Carcinoma via Antigen-Dependent and Fas/FasL Interactions. <i>Cancer Immunology Research</i> , 2018, 6, 1274-1287.	1.6	53
249	Engineering Platforms for T Cell Modulation. <i>International Review of Cell and Molecular Biology</i> , 2018, 341, 277-362.	1.6	8
250	Imaging T Cell Dynamics and Function Using PET and Human Nuclear Reporter Genes. <i>Methods in Molecular Biology</i> , 2018, 1790, 165-180.	0.4	4
251	PET Imaging of T Cells: Target Identification and Feasibility Assessment. <i>ChemMedChem</i> , 2018, 13, 1566-1579.	1.6	1
252	Human antibody-based chemically induced dimerizers for cell therapeutic applications. <i>Nature Chemical Biology</i> , 2018, 14, 112-117.	3.9	52
253	Driving cars to the clinic for solid tumors. <i>Gene Therapy</i> , 2018, 25, 165-175.	2.3	67
254	The promise and challenges of immune agonist antibody development in cancer. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 509-527.	21.5	270
255	Chimeric antigen receptor "cell therapy" a hematological success story. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 116-121.	0.3	6
256	Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E5859-E5866.	3.3	162
257	Hematopoietic Stem Cell Collections and Cellular Therapies. , 2018, , 151-167.		0
258	Cancer immunotherapy: Adoptive cell therapies, cytokine-related toxicities, and the kidneys. <i>Journal of Onco-Nephrology</i> , 2019, 3, 131-143.	0.3	0
259	Conjugated CAR T cell one step beyond conventional CAR T cell for a promising cancer immunotherapy. <i>Cellular Immunology</i> , 2019, 345, 103963.	1.4	9
260	Morphological lymphocytic reaction, patient prognosis and PD-1 expression after surgical resection for oesophageal cancer. <i>British Journal of Surgery</i> , 2019, 106, 1352-1361.	0.1	13
262	Induced pluripotent stem cells as a novel cancer vaccine. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1191-1197.	1.4	10
263	Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. <i>Molecular Cancer</i> , 2019, 18, 125.	7.9	201

#	ARTICLE	IF	CITATIONS
264	Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 ⁺ T Cells. <i>Cell</i> , 2019, 178, 1189-1204.e23.	13.5	189
265	The Role of Checkpoint Inhibitors and Cytokines in Adoptive Cell-Based Cancer Immunotherapy with Genetically Modified T Cells. <i>Biochemistry (Moscow)</i> , 2019, 84, 695-710.	0.7	5
266	Clinical update on head and neck cancer: molecular biology and ongoing challenges. <i>Cell Death and Disease</i> , 2019, 10, 540.	2.7	339
267	Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 5890-5900.	3.2	31
268	CAR T cells for brain tumors: Lessons learned and road ahead. <i>Immunological Reviews</i> , 2019, 290, 60-84.	2.8	151
269	Hierarchical assembly of hyaluronan coated albumin nanoparticles for pancreatic cancer chemoimmunotherapy. <i>Nanoscale</i> , 2019, 11, 16476-16487.	2.8	31
270	A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells. <i>Journal of Translational Medicine</i> , 2019, 17, 240.	1.8	18
271	The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 1574.	2.2	45
272	Gene editing: Towards the third generation of adoptive T-cell transfer therapies. <i>Immuno-Oncology Technology</i> , 2019, 1, 19-26.	0.2	7
273	Immunotherapy in Ovarian Cancer. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 447-464.	0.6	27
274	Emerging Approaches of Cell-Based Nanosystems to Target Cancer Metastasis. <i>Advanced Functional Materials</i> , 2019, 29, 1903441.	7.8	41
275	Vectofusin-1 Improves Transduction of Primary Human Cells with Diverse Retroviral and Lentiviral Pseudotypes, Enabling Robust, Automated Closed-System Manufacturing. <i>Human Gene Therapy</i> , 2019, 30, 1477-1493.	1.4	24
276	Local biomaterials-assisted cancer immunotherapy to trigger systemic antitumor responses. <i>Chemical Society Reviews</i> , 2019, 48, 5506-5526.	18.7	209
277	Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5010.	1.8	35
278	Advances in Engineering Cells for Cancer Immunotherapy. <i>Theranostics</i> , 2019, 9, 7889-7905.	4.6	44
279	Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 751-757.	0.2	19
280	CAR T Cells Beyond Cancer: Hope for Immunomodulatory Therapy of Infectious Diseases. <i>Frontiers in Immunology</i> , 2019, 10, 2711.	2.2	76
281	Development of molecular and pharmacological switches for chimeric antigen receptor T cells. <i>Experimental Hematology and Oncology</i> , 2019, 8, 27.	2.0	7

#	ARTICLE	IF	CITATIONS
282	Beta-Adrenergic Signaling in Tumor Immunology and Immunotherapy. <i>Critical Reviews in Immunology</i> , 2019, 39, 93-103.	1.0	16
284	Activation of invariant natural killer T cells stimulates adipose tissue remodeling via adipocyte death and birth in obesity. <i>Genes and Development</i> , 2019, 33, 1657-1672.	2.7	25
285	Interplay between dendritic cells and cancer cells. <i>International Review of Cell and Molecular Biology</i> , 2019, 348, 179-215.	1.6	37
286	Potential applications of nanoparticles for tumor microenvironment remodeling to ameliorate cancer immunotherapy. <i>International Journal of Pharmaceutics</i> , 2019, 570, 118636.	2.6	24
287	Genetically engineered T cells for cancer immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 35.	7.1	153
288	Gold Nanoparticle-Mediated Photoporation Enables Delivery of Macromolecules over a Wide Range of Molecular Weights in Human CD4+ T Cells. <i>Crystals</i> , 2019, 9, 411.	1.0	28
289	In situ thermal ablation of tumors in combination with nano-adjuvant and immune checkpoint blockade to inhibit cancer metastasis and recurrence. <i>Biomaterials</i> , 2019, 224, 119490.	5.7	59
290	Harnessing T-cell activity against prostate cancer: A therapeutic microparticulate oral cancer vaccine. <i>Vaccine</i> , 2019, 37, 6085-6092.	1.7	14
291	Adoptive cell transfer therapy for hepatocellular carcinoma. <i>Frontiers of Medicine</i> , 2019, 13, 3-11.	1.5	45
292	Genetic Modification Strategies to Enhance CAR T Cell Persistence for Patients With Solid Tumors. <i>Frontiers in Immunology</i> , 2019, 10, 218.	2.2	43
293	Cold Tumors: A Therapeutic Challenge for Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 168.	2.2	733
294	Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma. <i>Annals of Hematology</i> , 2019, 98, 813-822.	0.8	26
295	Quality Control and Nonclinical Research on CAR-T Cell Products: General Principles and Key Issues. <i>Engineering</i> , 2019, 5, 122-131.	3.2	37
296	NK cells specifically TCR-dressed to kill cancer cells. <i>EBioMedicine</i> , 2019, 40, 106-117.	2.7	56
297	Critical Care Management of Chimeric Antigen Receptor T Cell-related Toxicity. Be Aware and Prepared. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 20-23.	2.5	34
298	Redox-responsive interleukin-2 nanogel specifically and safely promotes the proliferation and memory precursor differentiation of tumor-reactive T-cells. <i>Biomaterials Science</i> , 2019, 7, 1345-1357.	2.6	58
299	Carbonic Anhydrase as Drug Target. , 2019, , .		8
300	Functional T cell activation by smart nanosystems for effective cancer immunotherapy. <i>Nano Today</i> , 2019, 27, 28-47.	6.2	34

#	ARTICLE	IF	CITATIONS
301	Cell sorting actuated by a microfluidic inertial vortex. <i>Lab on A Chip</i> , 2019, 19, 2456-2465.	3.1	25
302	Immunomodulatory Nanosystems. <i>Advanced Science</i> , 2019, 6, 1900101.	5.6	255
303	Chimeric antigen receptor preparation from hybridoma to T-cell expression. <i>Antibody Therapeutics</i> , 2019, 2, 56-63.	1.2	5
304	In Situ Modification of the Tumor Cell Surface with Immunomodulating Nanoparticles for Effective Suppression of Tumor Growth in Mice. <i>Advanced Materials</i> , 2019, 31, e1902542.	11.1	58
305	The road map of cancer precision medicine with the innovation of advanced cancer detection technology and personalized immunotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 596-603.	0.6	10
306	Novel Therapies in Paediatric NHL. , 2019, , 315-335.		0
307	T cell immunotherapy enhanced by designer biomaterials. <i>Biomaterials</i> , 2019, 217, 119265.	5.7	40
308	Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma. <i>Blood Advances</i> , 2019, 3, 1230-1243.	2.5	43
309	Toll-like receptor-targeted particles: A paradigm to manipulate the tumor microenvironment for cancer immunotherapy. <i>Acta Biomaterialia</i> , 2019, 94, 82-96.	4.1	40
310	Turning the Tide Against Regulatory T Cells. <i>Frontiers in Oncology</i> , 2019, 9, 279.	1.3	47
311	Can Exercise-Induced Modulation of the Tumor Physiologic Microenvironment Improve Antitumor Immunity?. <i>Cancer Research</i> , 2019, 79, 2447-2456.	0.4	41
312	Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy. <i>Annals of Neurology</i> , 2019, 86, 42-54.	2.8	124
313	Current Status of Immunotherapies for Treating Pancreatic Cancer. <i>Current Oncology Reports</i> , 2019, 21, 60.	1.8	38
314	CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071984158.	1.1	160
315	Advances in drug delivery for post-surgical cancer treatment. <i>Biomaterials</i> , 2019, 219, 119182.	5.7	129
316	Mechanisms of resistance to CAR T cell therapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 372-385.	12.5	518
317	Biomimetic Glyconanoparticle Vaccine for Cancer Immunotherapy. <i>ACS Nano</i> , 2019, 13, 2936-2947.	7.3	42
318	The Impact of Varying Cooling and Thawing Rates on the Quality of Cryopreserved Human Peripheral Blood T Cells. <i>Scientific Reports</i> , 2019, 9, 3417.	1.6	74

#	ARTICLE	IF	CITATIONS
319	In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	19
320	Methods to manufacture regulatory T cells for cell therapy. <i>Clinical and Experimental Immunology</i> , 2019, 197, 52-63.	1.1	76
321	Chimeric antigen receptor T cell therapy and other therapeutics for malignancies: Combination and opportunity. <i>International Immunopharmacology</i> , 2019, 70, 498-503.	1.7	21
322	Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors. <i>Cancer Discovery</i> , 2019, 9, 476-481.	7.7	48
323	Two-in-One Platform for High-Efficiency Intracellular Delivery and Cell Harvest: When a Photothermal Agent Meets a Thermoresponsive Polymer. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 12357-12366.	4.0	35
324	SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints. <i>Leukemia</i> , 2019, 33, 2585-2598.	3.3	29
325	Therapeutic targeting of trained immunity. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 553-566.	21.5	287
326	Understanding the Dynamics of T-Cell Activation in Health and Disease Through the Lens of Computational Modeling. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-8.	1.0	27
327	From synthetic biology to human therapy: engineered mammalian cells. <i>Current Opinion in Biotechnology</i> , 2019, 58, 108-116.	3.3	34
328	Computational Redesign of PD-1 Interface for PD-L1 Ligand Selectivity. <i>Structure</i> , 2019, 27, 829-836.e3.	1.6	13
329	Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy. <i>Advanced Healthcare Materials</i> , 2019, 8, e1801320.	3.9	43
330	Emerging Nano-µMicroapproaches for Cancer Immunotherapy. <i>Advanced Science</i> , 2019, 6, 1801847.	5.6	136
331	T cell engineered with a novel nanobody-based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy. <i>IUBMB Life</i> , 2019, 71, 1259-1267.	1.5	45
332	Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 18.	6.9	79
333	Clinical care of chimeric antigen receptor T-cell patients and managing immune-related adverse effects in the ambulatory and hospitalized setting: a review. <i>Future Oncology</i> , 2019, 15, 4235-4246.	1.1	5
334	Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 24275-24284.	3.3	67
335	Nursing management for adult recipients of CAR T-19 therapy. <i>Nurs Crit Care (Ambler)</i> , 2019, 14, 31-36.	0.3	1
336	Delivery strategies of cancer immunotherapy: recent advances and future perspectives. <i>Journal of Hematology and Oncology</i> , 2019, 12, 126.	6.9	96

#	ARTICLE	IF	CITATIONS
337	Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity. , 2019, 7, 330.		18
338	Engineering Nanoparticles to Reprogram the Tumor Immune Microenvironment for Improved Cancer Immunotherapy. <i>Theranostics</i> , 2019, 9, 7981-8000.	4.6	106
339	Orthogonal regulation of DNA nanostructure self-assembly and disassembly using antibodies. <i>Nature Communications</i> , 2019, 10, 5509.	5.8	63
340	Development of a Human Photoacoustic Imaging Reporter Gene Using the Clinical Dye Indocyanine Green. <i>Radiology Imaging Cancer</i> , 2019, 1, e190035.	0.7	15
341	CAR T Cell Therapy for Hematological Malignancies. <i>Current Medical Science</i> , 2019, 39, 874-882.	0.7	22
342	CAR T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope. <i>HemaSphere</i> , 2019, 3, e185.	1.2	33
343	Longitudinal Visualization of Viable Cancer Cell Intratumoral Distribution in Mouse Models Using Oatp1a1-Enhanced Magnetic Resonance Imaging. <i>Investigative Radiology</i> , 2019, 54, 302-311.	3.5	28
344	Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy. <i>Theranostics</i> , 2019, 9, 126-151.	4.6	128
345	Functional Nanomaterials Optimized to Circumvent Tumor Immunological Tolerance. <i>Advanced Functional Materials</i> , 2019, 29, 1806087.	7.8	21
346	Leveraging TCR Affinity in Adoptive Immunotherapy against Shared Tumor/Self-Antigens. <i>Cancer Immunology Research</i> , 2019, 7, 40-49.	1.6	17
347	Biomimetic Nanoparticle Vaccines for Cancer Therapy. <i>Advanced Biology</i> , 2019, 3, e1800219.	3.0	84
348	NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors. <i>Cancer Immunology Research</i> , 2019, 7, 363-375.	1.6	180
349	Delivery technologies for cancer immunotherapy. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 175-196.	21.5	1,562
350	T-cell receptor gene-modified cells: past promises, present methodologies and future challenges. <i>Cytotherapy</i> , 2019, 21, 341-357.	0.3	10
351	HTiP: High-Throughput Immunomodulator Phenotypic Screening Platform to Reveal IAP Antagonists as Anti-cancer Immune Enhancers. <i>Cell Chemical Biology</i> , 2019, 26, 331-339.e3.	2.5	33
352	CRISPR-Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics. <i>Cancer Cell International</i> , 2019, 19, 12.	1.8	46
353	Cancer diagnosis and immunotherapy in the age of CRISPR. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 233-243.	1.5	4
354	Exosomes: Isolation, Analysis, and Applications in Cancer Detection and Therapy. <i>ChemBioChem</i> , 2019, 20, 451-461.	1.3	92

#	ARTICLE	IF	CITATIONS
356	miR-155 expression in antitumor immunity: The higher the better?. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 208-218.	1.5	29
357	Computational Methods for Identification of T Cell Neopeptides in Tumors. <i>Methods in Molecular Biology</i> , 2019, 1878, 157-172.	0.4	16
358	Predictive and therapeutic biomarkers in chimeric antigen receptor T cell therapy: A clinical perspective. <i>Journal of Cellular Physiology</i> , 2019, 234, 5827-5841.	2.0	21
359	Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response. <i>Clinical Cancer Research</i> , 2019, 25, 1036-1049.	3.2	41
360	Multivalent Ligand Binding to Cell Membrane Antigens: Defining the Interplay of Affinity, Valency, and Expression Density. <i>Journal of the American Chemical Society</i> , 2019, 141, 251-261.	6.6	59
361	Cell-based immunotherapy approaches for multiple myeloma. <i>British Journal of Cancer</i> , 2019, 120, 38-44.	2.9	30
362	CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor Engineered T Cells. <i>Cancer Research</i> , 2019, 79, 663-675.	0.4	62
363	The effects of monocytes on tumor cell extravasation in a 3D vascularized microfluidic model. <i>Biomaterials</i> , 2019, 198, 180-193.	5.7	110
364	Genetic and phenotypic difference in CD8 ⁺ T cell exhaustion between chronic hepatitis B infection and hepatocellular carcinoma. <i>Journal of Medical Genetics</i> , 2019, 56, 18-21.	1.5	26
365	Addressing barriers to effective cancer immunotherapy with nanotechnology: achievements, challenges, and roadmap to the next generation of nanoimmunotherapeutics. <i>Advanced Drug Delivery Reviews</i> , 2019, 141, 3-22.	6.6	44
366	Biomimetic Nanotechnology toward Personalized Vaccines. <i>Advanced Materials</i> , 2020, 32, e1901255.	11.1	200
367	Advances of functional nanomaterials for cancer immunotherapeutic applications. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2020, 12, e1574.	3.3	10
368	Single peptides and combination modalities for triple negative breast cancer. <i>Journal of Cellular Physiology</i> , 2020, 235, 4089-4108.	2.0	8
369	Tumor microenvironment responsive drug delivery systems. <i>Asian Journal of Pharmaceutical Sciences</i> , 2020, 15, 416-448.	4.3	114
370	Smart Injectable Hydrogels for Cancer Immunotherapy. <i>Advanced Functional Materials</i> , 2020, 30, 1902785.	7.8	182
371	Emerging CAR T cell therapies: clinical landscape and patent technological routes. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 1424-1433.	1.4	10
372	Recent Advances in Molecular Imaging with Gold Nanoparticles. <i>Bioconjugate Chemistry</i> , 2020, 31, 303-314.	1.8	95
373	Engineering Molecular Machines for the Control of Cellular Functions for Diagnostics and Therapeutics. <i>Advanced Functional Materials</i> , 2020, 30, 1904345.	7.8	2

#	ARTICLE	IF	CITATIONS
374	Long-term surviving cancer patients as a source of therapeutic TCR. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 859-865.	2.0	16
376	Current challenges and emerging opportunities of CAR-T cell therapies. <i>Journal of Controlled Release</i> , 2020, 319, 246-261.	4.8	78
377	Important aspects of T cell collection by apheresis for manufacturing chimeric antigen receptor T cells. <i>Advances in Cell and Gene Therapy</i> , 2020, 3, e75.	0.6	6
378	Synthetic 3D scaffolds for cancer immunotherapy. <i>Current Opinion in Biotechnology</i> , 2020, 65, 1-8.	3.3	6
379	<scp>PTPN</scp> 2 phosphatase deletion in T cells promotes anti-tumour immunity and <scp>CAR</scp> T cell efficacy in solid tumours. <i>EMBO Journal</i> , 2020, 39, e103637.	3.5	79
380	Sheddable Prodrug Vesicles Combating Adaptive Immune Resistance for Improved Photodynamic Immunotherapy of Cancer. <i>Nano Letters</i> , 2020, 20, 353-362.	4.5	162
381	Cell Reprogramming for Immunotherapy. <i>Methods in Molecular Biology</i> , 2020, , .	0.4	2
382	Activating Macrophage-Mediated Cancer Immunotherapy by Genetically Edited Nanoparticles. <i>Advanced Materials</i> , 2020, 32, e2004853.	11.1	146
383	CCL21-loaded 3D hydrogels for T cell expansion and differentiation. <i>Biomaterials</i> , 2020, 259, 120313.	5.7	43
384	A Functional Screening Strategy for Engineering Chimeric Antigen Receptors with Reduced On-Target, Off-Tumor Activation. <i>Molecular Therapy</i> , 2020, 28, 2564-2576.	3.7	14
385	Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant. <i>Frontiers in Immunology</i> , 2020, 11, 577869.	2.2	147
386	Biomaterialized Bacterial Outer Membrane Vesicles Potentiate Safe and Efficient Tumor Microenvironment Reprogramming for Anticancer Therapy. <i>Advanced Materials</i> , 2020, 32, e2002085.	11.1	118
387	A Universal CAR-NK Cell Targeting Various Epitopes of HIV-1 gp160. <i>ACS Chemical Biology</i> , 2020, 15, 2299-2310.	1.6	27
388	Immunotherapy with CAR-T cells in paediatric haematology-oncology. <i>Anales De PediatrĀa (English) Tj ETQq1 1 0.784314 rgBT /Overlo</i>	0.1	0
389	Engineering Next-Generation CAR-T Cells for Better Toxicity Management. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8620.	1.8	38
390	A prognostic risk model based on immune-related genes predicts overall survival of patients with hepatocellular carcinoma. <i>Health Science Reports</i> , 2020, 3, e202.	0.6	2
391	Strategies to Enhance the Efficacy of T-Cell Therapy for Central Nervous System Tumors. <i>Frontiers in Immunology</i> , 2020, 11, 599253.	2.2	11
392	PMN-MDSCs-induced accumulation of CD8+CD39+ T cells predicts the efficacy of chemotherapy in esophageal squamous cell carcinoma. <i>Clinical and Translational Medicine</i> , 2020, 10, e232.	1.7	5

#	ARTICLE	IF	CITATIONS
393	Mechanical Immunoengineering of T cells for Therapeutic Applications. <i>Accounts of Chemical Research</i> , 2020, 53, 2777-2790.	7.6	24
394	Gene Augmentation and Editing to Improve TCR Engineered T Cell Therapy against Solid Tumors. <i>Vaccines</i> , 2020, 8, 733.	2.1	10
395	Chimeric antigen receptor T-cell therapy beyond cancer: current practice and future prospects. <i>Immunotherapy</i> , 2020, 12, 1021-1034.	1.0	3
396	Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on $\hat{\alpha}$ T and NK Cells. <i>Cells</i> , 2020, 9, 1757.	1.8	53
397	Interactive Effects of PD-L1 Expression in Tumor and Immune Cells on Prognosis of Esophageal Squamous Cell Carcinoma: A One-Center Retrospective Cohort Study. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 6565-6572.	1.0	4
398	The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 134.	7.1	84
399	Advances in local and systemic drug delivery systems for post-surgical cancer treatment. <i>Journal of Materials Chemistry B</i> , 2020, 8, 8507-8518.	2.9	30
400	Inflammatory Cells in Diffuse Large B Cell Lymphoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 2418.	1.0	29
401	Characterization of CAR T cell expansion and cytotoxic potential during Ex Vivo manufacturing using image-based cytometry. <i>Journal of Immunological Methods</i> , 2020, 484-485, 112830.	0.6	6
402	A brief review concerning Chimeric Antigen Receptors T cell therapy. <i>Journal of Cancer</i> , 2020, 11, 5424-5431.	1.2	4
403	Cell and tissue engineering in lymph nodes for cancer immunotherapy. <i>Advanced Drug Delivery Reviews</i> , 2020, 161-162, 42-62.	6.6	43
404	Redirecting Vesicular Transport to Improve Nonviral Delivery of Molecular Cargo. <i>Advanced Biology</i> , 2020, 4, e2000059.	3.0	5
405	Brief Overview of Chimeric Antigen Receptor-Mediated Immunotherapy for Glioblastoma Multiforme. , 2020, , 507-513.		0
406	Biomaterials as Local Niches for Immunomodulation. <i>Accounts of Chemical Research</i> , 2020, 53, 1749-1760.	7.6	73
407	Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence. <i>Advanced Science</i> , 2020, 7, 2001447.	5.6	30
408	Identification of Targets to Redirect CAR T Cells in Glioblastoma and Colorectal Cancer: An Arduous Venture. <i>Frontiers in Immunology</i> , 2020, 11, 565631.	2.2	24
409	Advances in non and minimal-invasive transcutaneous delivery of immunotherapy for cancer treatment. <i>Biomedicine and Pharmacotherapy</i> , 2020, 131, 110753.	2.5	4
410	Persistent STAT5 activation reprograms the epigenetic landscape in CD4 ⁺ T cells to drive polyfunctionality and antitumor immunity. <i>Science Immunology</i> , 2020, 5, .	5.6	40

#	ARTICLE	IF	CITATIONS
411	Covalent Organic Framework-Based Nanocomposite for Synergetic Photo-, Chemodynamic-, and Immunotherapies. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 43456-43465.	4.0	49
412	Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	140
413	Tuberculosisâ€™Cancer Parallels in Immune Response Regulation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6136.	1.8	9
414	Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 940-948.	1.5	78
415	Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 2967.	1.0	23
416	Current Perspectives on Therapies, Including Drug Delivery Systems, for Managing Glioblastoma Multiforme. <i>ACS Chemical Neuroscience</i> , 2020, 11, 2962-2977.	1.7	15
417	The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy. <i>Cell Communication and Signaling</i> , 2020, 18, 134.	2.7	28
419	Engineering CAR T Cells to Target the HIV Reservoir. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 410.	1.8	29
420	Arming Anti-EGFRvIII CAR-T With TGFÎ² Trap Improves Antitumor Efficacy in Glioma Mouse Models. <i>Frontiers in Oncology</i> , 2020, 10, 1117.	1.3	19
421	The update of chimeric antigen receptor-T cells therapy in glioblastoma. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 442-445.	0.6	5
422	Electroporation of NKG2D RNA CAR Improves VÎ³9VÎ²2Î±T Cell Responses against Human Solid Tumor Xenografts. <i>Molecular Therapy - Oncolytics</i> , 2020, 17, 421-430.	2.0	32
423	Advances in CAR T Therapy for Hematologic Malignancies. <i>Pharmacotherapy</i> , 2020, 40, 741-755.	1.2	11
424	High-affinity mutant Interleukin-13 targeted CAR T cells enhance delivery of clickable biodegradable fluorescent nanoparticles to glioblastoma. <i>Bioactive Materials</i> , 2020, 5, 624-635.	8.6	34
425	Enhancing the Efficacy of CAR T Cells in the Tumor Microenvironment of Pancreatic Cancer. <i>Cancers</i> , 2020, 12, 1389.	1.7	25
426	Influence of Innate Immunity on Cancer Cell Stemness. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3352.	1.8	20
427	Mimetic Heat Shock Protein Mediated Immune Process to Enhance Cancer Immunotherapy. <i>Nano Letters</i> , 2020, 20, 4454-4463.	4.5	58
428	Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 659-684.	1.9	15
429	Value and affordability of CAR T-cell therapy in the United States. <i>Bone Marrow Transplantation</i> , 2020, 55, 1706-1715.	1.3	66

#	ARTICLE	IF	CITATIONS
430	Engineered biomaterials for cancer immunotherapy. <i>MedComm</i> , 2020, 1, 35-46.	3.1	52
431	Chimeric Antigen Receptor T Cell Therapy Comes to Clinical Practice. <i>Current Oncology</i> , 2020, 27, 115-123.	0.9	26
432	Scaffold-Mediated Static Transduction of T Cells for CAR T Cell Therapy. <i>Advanced Healthcare Materials</i> , 2020, 9, e2000275.	3.9	15
433	Genetically modified immune cells targeting tumor antigens. , 2020, 214, 107603.		17
434	Experimental treatment of colorectal cancer in mice with human T cells electroporated with NKG2D RNA CAR. <i>Immunotherapy</i> , 2020, 12, 733-748.	1.0	10
435	Parallel evolution of polymer chemistry and immunology: Integrating mechanistic biology with materials design. <i>Advanced Drug Delivery Reviews</i> , 2020, 156, 65-79.	6.6	15
436	The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice. <i>Frontiers in Immunology</i> , 2020, 11, 888.	2.2	45
437	HBV induced hepatocellular carcinoma and related potential immunotherapy. <i>Pharmacological Research</i> , 2020, 159, 104992.	3.1	57
438	Metabolism in tumor microenvironment: Implications for cancer immunotherapy. <i>MedComm</i> , 2020, 1, 47-68.	3.1	93
439	Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	150
440	Next-generation stem cells "ushering in a new era of cell-based therapies. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 463-479.	21.5	161
441	Modeling immune cell behavior across scales in cancer. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2020, 12, e1484.	6.6	24
442	Glycoengineering of Natural Killer Cells with CD22 Ligands for Enhanced Anticancer Immunotherapy. <i>ACS Central Science</i> , 2020, 6, 382-389.	5.3	49
443	Adaptive Nanoparticle Platforms for High Throughput Expansion and Detection of Antigen-Specific T cells. <i>Nano Letters</i> , 2020, 20, 6289-6298.	4.5	16
444	Pre-existing inflammatory immune microenvironment predicts the clinical response of vulvar high-grade squamous intraepithelial lesions to therapeutic HPV16 vaccination. , 2020, 8, e000563.		23
445	Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy. <i>Science Advances</i> , 2020, 6, eaba8564.	4.7	66
446	ROR γ Regulates Cholesterol Metabolism of CD8+ T Cells for Anticancer Immunity. <i>Cancers</i> , 2020, 12, 1733.	1.7	25
447	CAR T cells and checkpoint inhibition for the treatment of glioblastoma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 579-591.	1.4	37

#	ARTICLE	IF	CITATIONS
448	Bidirectional Crosstalk Between Cancer Stem Cells and Immune Cell Subsets. <i>Frontiers in Immunology</i> , 2020, 11, 140.	2.2	69
450	Advanced biomaterials for cancer immunotherapy. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 911-927.	2.8	62
451	Improving Cancer Immunotherapy with CRISPR-Based Technology. <i>Advanced Biology</i> , 2020, 4, e1900253.	3.0	6
452	STAT3 Inhibits CD103+ cDC1 Vaccine Efficacy in Murine Breast Cancer. <i>Cancers</i> , 2020, 12, 128.	1.7	14
453	Molecular Imaging for Cancer Immunotherapy: Seeing Is Believing. <i>Bioconjugate Chemistry</i> , 2020, 31, 404-415.	1.8	31
454	Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering. <i>Nano Letters</i> , 2020, 20, 1578-1589.	4.5	299
455	Prospects of biological and synthetic pharmacotherapies for glioblastoma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 305-317.	1.4	16
456	<p>Self-Assembled Nanoparticles Prepared from Low-Molecular-Weight PEI and Low-Generation PAMAM for EGFRvIII-Chimeric Antigen Receptor Gene Loading and T-Cell Transient Modification</p>. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 483-495.	3.3	32
457	Cellular immunotherapy: a clinical state-of-the-art of a new paradigm for cancer treatment. <i>Clinical and Translational Oncology</i> , 2020, 22, 1923-1937.	1.2	14
458	Blood components from pluripotent stem cells. , 2020, , 765-784.		0
459	Reprogramming Tumor Microenvironment with Photothermal Therapy. <i>Bioconjugate Chemistry</i> , 2020, 31, 1268-1278.	1.8	66
460	Advances in living cell-based anticancer therapeutics. <i>Biomaterials Science</i> , 2020, 8, 2344-2365.	2.6	22
461	Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103 ⁺ conventional dendritic cells. , 2020, 8, e000474.		57
462	Organoid Models of Glioblastoma to Study Brain Tumor Stem Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 220.	1.8	38
463	Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth. <i>Cells</i> , 2020, 9, 998.	1.8	64
464	Preclinical Studies of the Off-Target Reactivity of AFP158-Specific TCR Engineered T Cells. <i>Frontiers in Immunology</i> , 2020, 11, 607.	2.2	17
465	Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies. <i>Cell</i> , 2020, 181, 728-744.e21.	13.5	131
466	Dissecting the Tumor Immune Landscape in Chimeric Antigen Receptor T-cell Therapy: Key Challenges and Opportunities for a Systems Immunology Approach. <i>Clinical Cancer Research</i> , 2020, 26, 3505-3513.	3.2	18

#	ARTICLE	IF	CITATIONS
467	Platelet membrane-coated nanoparticles for targeted drug delivery and local chemo-photothermal therapy of orthotopic hepatocellular carcinoma. <i>Journal of Materials Chemistry B</i> , 2020, 8, 4648-4659.	2.9	56
468	Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia. <i>Blood</i> , 2020, 135, 713-723.	0.6	123
469	Biomaterial scaffold-based local drug delivery systems for cancer immunotherapy. <i>Science Bulletin</i> , 2020, 65, 1489-1504.	4.3	53
470	T-cell“engaging Therapy for Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 1595-1603.	3.2	21
471	Phthalocyanine-based photosensitizers combined with anti-PD-L1 for highly efficient photodynamic immunotherapy. <i>Dyes and Pigments</i> , 2021, 185, 108907.	2.0	15
472	Lentiviral vector bioprocess economics for cell and gene therapy commercialization. <i>Biochemical Engineering Journal</i> , 2021, 167, 107868.	1.8	26
473	Regulatory T Cell Therapy Following Liver Transplantation. <i>Liver Transplantation</i> , 2021, 27, 264-280.	1.3	18
474	The toxicity of cell therapy: Mechanism, manifestations, and challenges. <i>Journal of Applied Toxicology</i> , 2021, 41, 659-667.	1.4	7
475	Systemic tumour suppression via the preferential accumulation of erythrocyte-anchored chemokine-encapsulating nanoparticles in lung metastases. <i>Nature Biomedical Engineering</i> , 2021, 5, 441-454.	11.6	57
476	Chimeric antigen receptor (CAR) natural killer (NK)“cell therapy: leveraging the power of innate immunity. <i>British Journal of Haematology</i> , 2021, 193, 216-230.	1.2	61
477	Nanoenabled Tumor Oxygenation Strategies for Overcoming Hypoxia-Associated Immunosuppression. <i>ACS Applied Bio Materials</i> , 2021, 4, 277-294.	2.3	6
478	Engineering precision therapies: lessons and motivations from the clinic. <i>Synthetic Biology</i> , 2021, 6, ysaa024.	1.2	5
479	CAR-T cell engineering with CCR6 exhibits superior anti-solid tumor efficacy. <i>Science Bulletin</i> , 2021, 66, 755-756.	4.3	3
480	Emerging Immunotherapies in the Treatment of Brain Metastases. <i>Oncologist</i> , 2021, 26, 231-241.	1.9	29
481	Progress and perspective of microneedle system for anti-cancer drug delivery. <i>Biomaterials</i> , 2021, 264, 120410.	5.7	65
482	Nanoparticles in cancer immunotherapies: An innovative strategy. <i>Biotechnology Progress</i> , 2021, 37, e3070.	1.3	14
483	Chimeric Antigen Receptor beyond CAR-T Cells. <i>Cancers</i> , 2021, 13, 404.	1.7	29
484	Cancer Biology, Epidemiology, and Treatment in the 21st Century: Current Status and Future Challenges From a Biomedical Perspective. <i>Cancer Control</i> , 2021, 28, 107327482110387.	0.7	8

#	ARTICLE	IF	CITATIONS
485	Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine. <i>Onc Immunology</i> , 2021, 10, 1899469.	2.1	28
486	The Future of Transplantation: Hope, Investigative Discipline, and Fairness. <i>Organ and Tissue Transplantation</i> , 2021, , 733-740.	0.0	0
487	Cell and gene therapiesâ€”Emerging technologies and drug delivery systems for treating brain cancer. , 2021, , 431-446.		0
488	Copper Sulfide Nanoparticleâ€”Redirected Macrophages for Adoptive Transfer Therapy of Melanoma. <i>Advanced Functional Materials</i> , 2021, 31, 2008022.	7.8	21
489	Understanding the Role of Plasticity in Glioblastoma. , 2021, , .		0
490	CD27 enhances the killing effect of CAR T cells targeting trophoblast cell surface antigen 2 in the treatment of solid tumors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2059-2071.	2.0	31
491	Antitumor activity of the third generation EphA2 CAR-T cells against glioblastoma is associated with interferon gamma induced PD-L1. <i>Onc Immunology</i> , 2021, 10, 1960728.	2.1	20
492	Targeting Glioblastoma: The Current State of Different Therapeutic Approaches. <i>Current Neuropharmacology</i> , 2021, 19, 1701-1715.	1.4	12
493	Hypothesis: Immunotherapy by Selective Convalescent Blood Engineering to Stifle Diseases like COVID-19. <i>International Journal of Medical Sciences</i> , 2021, 18, 3389-3394.	1.1	0
494	Carbohydrate Systems in Targeted Drug Delivery: Expectation and Reality. <i>Russian Journal of Bioorganic Chemistry</i> , 2021, 47, 71-98.	0.3	5
495	Nanotechnology-enabled Chemodynamic Therapy and Immunotherapy. <i>Current Cancer Drug Targets</i> , 2021, 21, 545-557.	0.8	20
496	Cellular therapy for the treatment of solid tumors. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103056.	0.5	10
499	Cell-derived vesicles for delivery of cancer immunotherapy. <i>Exploration of Medicine</i> , 0, , .	1.5	0
500	Cell-derived vesicles for delivery of cancer immunotherapy. <i>Exploration of Medicine</i> , 0, , .	1.5	1
501	Oxygen-independent free radical generation mediated by core-shell magnetic nanocomposites synergizes with immune checkpoint blockade for effective primary and metastatic tumor treatment. <i>Nano Today</i> , 2021, 36, 101024.	6.2	13
502	Regulatory Cell Therapy in Organ Transplantation: Achievements and Open Questions. <i>Frontiers in Immunology</i> , 2021, 12, 641596.	2.2	9
503	Genetic engineering of T cells for immunotherapy. <i>Nature Reviews Genetics</i> , 2021, 22, 427-447.	7.7	63
505	Against the Resilience of High-Grade Gliomas: The Immunotherapeutic Approach (Part I). <i>Brain Sciences</i> , 2021, 11, 386.	1.1	14

#	ARTICLE	IF	CITATIONS
506	Cell Therapies in Bladder Cancer Management. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2818.	1.8	8
507	Nanoengineered CAR \times Biohybrids for Solid Tumor Immunotherapy with Microenvironment Photothermal \times Remodeling Strategy. <i>Small</i> , 2021, 17, e2007494.	5.2	44
508	COL1A1 is a prognostic biomarker and correlated with immune infiltrates in lung cancer. <i>PeerJ</i> , 2021, 9, e11145.	0.9	33
509	Engineered Cytokines for Cancer and Autoimmune Disease Immunotherapy. <i>Advanced Healthcare Materials</i> , 2021, 10, e2002214.	3.9	19
510	Targeting the Tumor Microenvironment for Improving Therapeutic Effectiveness in Cancer Immunotherapy: Focusing on Immune Checkpoint Inhibitors and Combination Therapies. <i>Cancers</i> , 2021, 13, 1188.	1.7	27
511	CAR T-Cell Production Using Nonviral Approaches. <i>Journal of Immunology Research</i> , 2021, 2021, 1-9.	0.9	31
512	Rational nanocarrier design towards clinical translation of cancer nanotherapy. <i>Biomedical Materials (Bristol)</i> , 2021, 16, 032005.	1.7	14
513	Shaping Functional Avidity of CAR T Cells: Affinity, Avidity, and Antigen Density That Regulate Response. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 872-884.	1.9	26
514	High drug loading and pH-responsive nanomedicines driven by dynamic boronate covalent chemistry for potent cancer immunotherapy. <i>Nano Research</i> , 2021, 14, 3913-3920.	5.8	11
515	Nanomedicine \times Boosting Tumor Immunogenicity for Enhanced Immunotherapy. <i>Advanced Functional Materials</i> , 2021, 31, 2011171.	7.8	84
516	Extremely High-Throughput Parallel Microfluidic Vortex-Actuated Cell Sorting. <i>Micromachines</i> , 2021, 12, 389.	1.4	6
517	Pharmacologic Control of CAR T Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4320.	1.8	9
518	Immune Checkpoints in Pediatric Solid Tumors: Targetable Pathways for Advanced Therapeutic Purposes. <i>Cells</i> , 2021, 10, 927.	1.8	8
519	Cancer Immunology and CAR-T Cells: A Turning Point Therapeutic Approach in Colorectal Carcinoma with Clinical Insight. <i>Current Molecular Medicine</i> , 2021, 21, 221-236.	0.6	6
520	The confounding effect of interleukin-6 on apoptosis of MCF-7 cells through down-regulation of MMP-2/-9 mRNA expression. <i>Turkish Journal of Biochemistry</i> , 2021, 46, 549-555.	0.3	7
521	Single \times Domain Multiferroic Array \times Addressable Terfenol \times D (SMARt) Micromagnets for Programmable Single \times Cell Capture and Release. <i>Advanced Materials</i> , 2021, 33, e2006651.	11.1	20
522	Reactions Related to CAR-T Cell Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 663201.	2.2	54
523	Emerging Trends in Immunomodulatory Nanomaterials Toward Cancer Therapy. <i>Synthesis Lectures on Biomedical Engineering</i> , 2021, 16, i-84.	0.1	0

#	ARTICLE	IF	CITATIONS
524	Chimeric CTLA4-CD28-CD3z T Cells Potentiate Antitumor Activity Against CD80/CD86-Positive B Cell Malignancies. <i>Frontiers in Immunology</i> , 2021, 12, 642528.	2.2	10
525	Immune Landscape of Thyroid Cancers: New Insights. <i>Frontiers in Endocrinology</i> , 2020, 11, 637826.	1.5	30
526	Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets. <i>Nature Biomedical Engineering</i> , 2021, 5, 1038-1047.	11.6	164
527	Bispecific antibodies come to the aid of cancer immunotherapy. <i>Molecular Oncology</i> , 2021, 15, 1759-1763.	2.1	3
528	Generation of highly proliferative, rejuvenated cytotoxic T cell clones through pluripotency reprogramming for adoptive immunotherapy. <i>Molecular Therapy</i> , 2021, 29, 3027-3041.	3.7	19
529	A Novel off-the-Shelf Trastuzumab-Armed NK Cell Therapy (ACE1702) Using Antibody-Cell-Conjugation Technology. <i>Cancers</i> , 2021, 13, 2724.	1.7	19
530	Recent Advances in Engineered Materials for Immunotherapy-Involved Combination Cancer Therapy. <i>Advanced Materials</i> , 2021, 33, e2007630.	11.1	112
531	TP53-Mutated Circulating Tumor DNA for Disease Monitoring in Lymphoma Patients after CAR T Cell Therapy. <i>Diagnostics</i> , 2021, 11, 844.	1.3	2
532	Developing a Novel Anticancer Gold(III) Agent to Integrate Chemotherapy and Immunotherapy. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 6777-6791.	2.9	23
533	Near Infrared Photoimmunotherapy; A Review of Targets for Cancer Therapy. <i>Cancers</i> , 2021, 13, 2535.	1.7	47
534	Immunotherapy for Breast Cancer Treatment. <i>Iranian Biomedical Journal</i> , 2021, 25, 140-156.	0.4	2
535	Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy. <i>Cancer Cell International</i> , 2021, 21, 262.	1.8	31
536	Nanotechnology synergized immunoengineering for cancer. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 163, 72-101.	2.0	8
537	JAK/STAT-Dependent Chimeric Antigen Receptor (CAR) Expression: A Design Benefiting From a Dual AND/OR Gate Aiming to Increase Specificity, Reduce Tumor Escape and Affect Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2021, 12, 638639.	2.2	7
538	Melanoma reactive TCR-modified T cells generated without activation retain a less differentiated phenotype and mediate a superior in vivo response. <i>Scientific Reports</i> , 2021, 11, 13327.	1.6	8
539	Programmable, Multiplexed DNA Circuits Supporting Clinically Relevant, Electrochemical Antibody Detection. <i>ACS Sensors</i> , 2021, 6, 2442-2448.	4.0	32
540	Remote controlling of CAR-T cells and toxicity management: Molecular switches and next generation CARs. <i>Translational Oncology</i> , 2021, 14, 101070.	1.7	17
541	Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme. <i>Cancer Medicine</i> , 2021, 10, 5019-5030.	1.3	13

#	ARTICLE	IF	CITATIONS
542	Bio-Nanocarriers for Lung Cancer Management: Befriending the Barriers. <i>Nano-Micro Letters</i> , 2021, 13, 142.	14.4	16
543	New targets for CAR T therapy in hematologic malignancies. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101277.	0.7	9
544	Biphasic response of T cell activation to substrate stiffness. <i>Biomaterials</i> , 2021, 273, 120797.	5.7	20
545	Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering. <i>Cell Reports</i> , 2021, 35, 109207.	2.9	91
546	NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6665.	1.8	11
547	CAR-macrophage: A new immunotherapy candidate against solid tumors. <i>Biomedicine and Pharmacotherapy</i> , 2021, 139, 111605.	2.5	92
548	Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder. <i>Frontiers in Oncology</i> , 2021, 11, 709370.	1.3	11
549	Extracellular Vesicles as an Advanced Delivery Biomaterial for Precision Cancer Immunotherapy. <i>Advanced Healthcare Materials</i> , 2022, 11, e2100650.	3.9	27
550	Oncolytic Viruses for Malignant Glioma: On the Verge of Success?. <i>Viruses</i> , 2021, 13, 1294.	1.5	28
551	Lipophilic recombinant-protein insertion endows lymphocytes with enhanced targeting-infiltration ability in EGFR positive cancer. <i>Cellular Immunology</i> , 2021, 365, 104376.	1.4	0
552	Non-viral transfection technologies for next-generation therapeutic T cell engineering. <i>Biotechnology Advances</i> , 2021, 49, 107760.	6.0	33
553	Immunotherapies in Non-Hodgkinâ€™s Lymphoma. <i>Cancers</i> , 2021, 13, 3625.	1.7	5
554	Advances in Adoptive Cellular Therapy (ACT). , 0, , .		0
555	Immunotherapy in Glioblastoma: A Clinical Perspective. <i>Cancers</i> , 2021, 13, 3721.	1.7	16
556	Polymeric microneedleâ€‘mediated sustained release systems: Design strategies and promising applications for drug delivery. <i>Asian Journal of Pharmaceutical Sciences</i> , 2022, 17, 70-86.	4.3	38
557	Recent Advances in Microfluidic Platforms for Programming Cellâ€‘Based Living Materials. <i>Advanced Materials</i> , 2021, 33, e2005944.	11.1	26
558	CAR Macrophages for SARS-CoV-2 Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 669103.	2.2	21
559	Overview of implantable and injectable biomaterials in immunotherapy. <i>GSC Biological and Pharmaceutical Sciences</i> , 2021, 16, 195-201.	0.1	0

#	ARTICLE	IF	CITATIONS
560	Biological basis for novel mesothelioma therapies. <i>British Journal of Cancer</i> , 2021, 125, 1039-1055.	2.9	14
561	Immunometabolism: A "Hot" Switch for "Cold" Pediatric Solid Tumors. <i>Trends in Cancer</i> , 2021, 7, 751-757.		8
562	Increased tumor-infiltrating lymphocyte density is associated with favorable outcomes in a comparative study of canine histiocytic sarcoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 807-818.	2.0	8
563	Tolerogenic Dendritic Cell-Based Approaches in Autoimmunity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8415.	1.8	30
564	The role of immunogenic cell death in gastrointestinal cancer immunotherapy (Review). <i>Biomedical Reports</i> , 2021, 15, 86.	0.9	1
565	DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application. <i>Clinical Epigenetics</i> , 2021, 13, 166.	1.8	85
566	Genome Editing in Medicine: Tools and Challenges. <i>Acta Medica Lituanica</i> , 2021, 28, 8.	0.2	2
567	Kidney Transplant T Cell-Mediated Rejection Occurring After Anti-CD19 CAR T-Cell Therapy for Refractory Aggressive Burkitt-like Lymphoma With 11q Aberration: A Case Report. <i>American Journal of Kidney Diseases</i> , 2022, 79, 760-764.	2.1	15
568	Recent advances in cancer immunotherapy. <i>Discover Oncology</i> , 2021, 12, 27.	0.8	14
569	Advances in CAR design. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101304.	0.7	4
570	Cryopreservation of NK and T Cells Without DMSO for Adoptive Cell-Based Immunotherapy. <i>BioDrugs</i> , 2021, 35, 529-545.	2.2	17
572	SAGE1: a Potential Target Antigen for Lung Cancer T-Cell Immunotherapy. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2302-2313.	1.9	6
573	Chimeric antigen receptor T-cell therapy for breast cancer. <i>Future Oncology</i> , 2021, 17, 2961-2979.	1.1	0
574	ACNPD: The Database for Elucidating the Relationships Between Natural Products, Compounds, Molecular Mechanisms, and Cancer Types. <i>Frontiers in Pharmacology</i> , 2021, 12, 746067.	1.6	5
575	Nanotechnology-based immunotherapies to combat cancer metastasis. <i>Molecular Biology Reports</i> , 2021, 48, 6563-6580.	1.0	8
576	Remodeling of Tumor Microenvironment by Tumor-Targeting Nanozymes Enhances Immune Activation of CAR T Cells for Combination Therapy. <i>Small</i> , 2021, 17, e2102624.	5.2	36
577	Recent Strategies to Develop Innovative Photosensitizers for Enhanced Photodynamic Therapy. <i>Chemical Reviews</i> , 2021, 121, 13454-13619.	23.0	657
578	High-Affinity Chimeric Antigen Receptor With Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms. <i>Frontiers in Oncology</i> , 2021, 11, 664236.	1.3	14

#	ARTICLE	IF	CITATIONS
579	Current Status and Opportunities in Adaptive Data Analysis for Therapeutic Cell Manufacturing. Current Opinion in Biomedical Engineering, 2021, 20, 100351.	1.8	1
580	Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma. Cancers, 2021, 13, 4787.	1.7	14
581	A Fully Integrated Online Platform For Real Time Monitoring Of Multiple Product Quality Attributes In Biopharmaceutical Processes For Monoclonal Antibody Therapeutics. Journal of Pharmaceutical Sciences, 2022, 111, 358-367.	1.6	31
582	Systemic inhibition of PTPN22 augments anticancer immunity. Journal of Clinical Investigation, 2021, 131, .	3.9	24
583	Engineered platelets: Advocates for tumor immunotherapy. Nano Today, 2021, 40, 101281.	6.2	15
584	Short Review on Advances in Hydrogel-Based Drug Delivery Strategies for Cancer Immunotherapy. Tissue Engineering and Regenerative Medicine, 2022, 19, 263-280.	1.6	11
585	Targeting natural killer cells in cancer immunotherapy. , 2022, , 63-82.		1
586	Engineering solutions to design CAR-T cells. , 2022, , 1-31.		0
587	Assessing Oximetry Response to Chimeric Antigen Receptor T-cell Therapy against Glioma with 19F MRI in a Murine Model. Radiology Imaging Cancer, 2021, 3, e200062.	0.7	7
588	CAR T Cells for Hematologic Malignancies. , 2021, , 829-846.		0
589	Advances in pluripotent stem cell-derived natural killer cells for cancer immunotherapy. , 2021, , 165-181.		0
590	Cerebrospinal Fluid Biomarkers in Childhood Leukemias. Cancers, 2021, 13, 438.	1.7	4
591	Using the Inducible Caspase-9 Suicide-Safeguard System with iPSC and Bioluminescent Tracking. Methods in Molecular Biology, 2019, 2048, 259-264.	0.4	2
592	Flow Cytometer Performance Characterization, Standardization, and Control. Series in Bioengineering, 2017, , 171-199.	0.3	5
593	Multimodal stratified imaging of nanovaccines in lymph nodes for improving cancer immunotherapy. Advanced Drug Delivery Reviews, 2020, 161-162, 145-160.	6.6	21
594	Targeting acute myeloid leukemia stem cells: Current therapies in development and potential strategies with new dimensions. Critical Reviews in Oncology/Hematology, 2020, 152, 102993.	2.0	16
595	Gene editing and CRISPR in the clinic: current and future perspectives. Bioscience Reports, 2020, 40, .	1.1	122
602	Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science, 2019, 365, 162-168.	6.0	282

#	ARTICLE	IF	CITATIONS
603	Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity. JCI Insight, 2020, 5, .	2.3	30
604	Anticancer Drugs and the Nervous System. CONTINUUM Lifelong Learning in Neurology, 2020, 26, 732-764.	0.4	13
605	Advanced Therapy Medicinal Products Challenges and Perspectives in Regenerative Medicine. Journal of Clinical Medicine Research, 2020, 12, 780-786.	0.6	24
606	EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC. Aging, 2019, 11, 11054-11072.	1.4	52
607	Tumor-specific hepatic stellate cells (tHSCs) induces DlgR2 expression in dendritic cells to inhibit T cells. Oncotarget, 2017, 8, 55084-55093.	0.8	7
608	Biological Therapy of Hematologic Malignancies: Toward a Chemotherapy- free Era. Current Medicinal Chemistry, 2019, 26, 1002-1018.	1.2	11
609	Deepening a Simple Question: Can MSCs Be Used to Treat Cancer?. Anticancer Research, 2017, 37, 4747-4758.	0.5	13
610	Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies. Immunotherapy, 2020, 12, 1341-1357.	1.0	3
611	Genome-Editing and Biomedical Cell Products: Current State, Safety and Efficacy. BIOpreparations Prevention Diagnosis Treatment, 2018, 18, 140-149.	0.2	5
612	Adaptor CAR Platformsâ€™Next Generation of T Cell-Based Cancer Immunotherapy. Cancers, 2020, 12, 1302.	1.7	45
613	CAR Tâ€™cell therapy for gastric cancer: Potential and perspective (Review). International Journal of Oncology, 2020, 56, 889-899.	1.4	5
614	HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activation. Oncology Letters, 2017, 14, 4415-4427.	0.8	60
615	Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma. ELife, 2020, 9, .	2.8	13
616	Multifunctional Gold Nanostars for Sensitive Detection, Photothermal Treatment and Immunotherapy of Brain Tumor. Bioanalysis, 2021, , 235-255.	0.1	0
617	Development of multifunctional nanopipettes for controlled intracellular delivery and single-entity detection. Faraday Discussions, 2021, 233, 315-335.	1.6	2
618	Homeostatic cytokines tune naivety and stemness of cord blood-derived transgenic T cells. Cancer Gene Therapy, 2021, , .	2.2	2
619	Advances in immune therapies in hematological malignancies. Journal of Internal Medicine, 2022, 292, 205-220.	2.7	5
620	Adoptive T-cell therapy for Hodgkin lymphoma. Blood Advances, 2021, 5, 4291-4302.	2.5	11

#	ARTICLE	IF	CITATIONS
621	A topography of immunotherapies against gastrointestinal malignancies. <i>Panminerva Medica</i> , 2022, 64, .	0.2	3
622	Finding the volume dial in stem cell manufacturing: Bioinspired and bioengineered approaches to scale up. <i>Current Opinion in Biomedical Engineering</i> , 2021, 20, 100356.	1.8	0
623	The TNF- α /TNFR2 Pathway: Targeting a Brake to Release the Anti-tumor Immune Response. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 725473.	1.8	21
624	Identification of Novel Modalities Through Bibliometric Analysis for Timely Development of Regulatory Guidance: A Case Study of T Cell Immunity. <i>Frontiers in Medicine</i> , 2021, 8, 756870.	1.2	2
625	Understanding and improving cellular immunotherapies against cancer: From cell-manufacturing to tumor-immune models. <i>Advanced Drug Delivery Reviews</i> , 2021, 179, 114003.	6.6	20
626	T Cell Immunotherapy: From Synthetic Biology to Clinical Practice. , 2015, , 217-230.		0
627	Th17 Cells: Can Epigenetic Manipulation and Artificial T cell Receptors Make Th17 cells Efficient Immunotherapeutic Anti-Tumor Effector T Cells?. <i>MOJ Immunology</i> , 2016, 4, .	11.0	0
629	DlgR2 knockdown boosts dendritic cell activity and inhibits hepatocellular carcinoma tumor <i>in-situ</i> growth. <i>Oncotarget</i> , 2017, 8, 54993-55002.	0.8	2
630	Synergizing genome editing and cancer immunotherapy. <i>Translational Cancer Research</i> , 2017, 6, S969-S972.	0.4	0
632	Regulatory Considerations for Genetically Manipulated Cell-Based Products. , 2018, , 295-295.		0
634	Road to Cancer Cureâ€“So Near and Yet So Far. <i>Journal of Medical Academics</i> , 2018, 1, 94-101.	0.1	0
635	Manufacturing of CD19 Specific CAR T-Cells and Evaluation of their Functional Activity in Vitro. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2018, 11, 1-9.	0.1	7
639	Development of Therapeutic Antibodies Against Carbonic Anhydrases. , 2019, , 305-322.		0
641	Principles of Immuno-Oncology. , 2019, , 113-120.		0
642	Novel Immunotherapies and Novel Combinations of Immunotherapy. , 2019, , 1-22.		0
643	METHODS OF CREATION OF ORTHOTOPIC MODELS OF HUMAN COLON CANCER IN IMMUNODEFICIENT ANIMALS. <i>Voprosy Onkologii</i> , 2019, 65, 303-307.	0.1	4
646	Identification of Cell Surface Targets for CAR T Cell Immunotherapy. <i>Methods in Molecular Biology</i> , 2020, 2097, 45-54.	0.4	3
647	Nrf2 activation mediates tumor-specific hepatic stellate cells-induced DlgR2 expression in dendritic cells. <i>Aging</i> , 2019, 11, 11565-11575.	1.4	2

#	ARTICLE	IF	CITATIONS
651	High-Throughput and Dosage-Controlled Intracellular Delivery of Large Cargos by an Acoustic-Electric Microvortices Platform. <i>Advanced Science</i> , 2022, 9, e2102021.	5.6	18
652	Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11781.	1.8	30
653	CAR-T Cell Clinical Trials Experience – Past, Present and Future. , 2020, , 303-375.		0
654	The Future of Transplantation: Hope, Investigative Discipline, and Fairness. <i>Organ and Tissue Transplantation</i> , 2020, , 1-8.	0.0	0
655	E3 ligase FBXW7 restricts M2-like tumor-associated macrophage polarization by targeting c-Myc. <i>Aging</i> , 2020, 12, 24394-24423.	1.4	17
657	Novel Immunotherapies and Novel Combinations of Immunotherapy for Metastatic Melanoma. , 2020, , 1165-1186.		0
658	Chimeric antigen receptor T-cell therapy in hematopoietic and nonhematopoietic malignancies. <i>Biomedical and Biotechnology Research Journal</i> , 2020, 4, 179.	0.3	0
659	Next Generation of Adoptive T Cell Therapy Using CRISPR/Cas9 Technology: Universal or Boosted?. <i>Methods in Molecular Biology</i> , 2020, 2115, 407-417.	0.4	1
660	Genetically Programmable Fusion Cellular Vesicles for Cancer Immunotherapy. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 26320-26326.	7.2	55
661	Genetically Programmable Fusion Cellular Vesicles for Cancer Immunotherapy. <i>Angewandte Chemie</i> , 2021, 133, 26524-26530.	1.6	2
663	T-Cell Immunotherapy: From Synthetic Biology to Clinical Practice. , 2021, , 199-218.		0
664	Fundamentals to clinical application of nanoparticles in cancer immunotherapy and radiotherapy. <i>E-cancermedicalscience</i> , 2020, 14, 1095.	0.6	2
666	Synergistic anti-tumor effect of anti-PD-L1 antibody cationic microbubbles for delivery of the miR-34a gene combined with ultrasound on cervical carcinoma. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 988-1005.	0.0	1
667	Cyclooxygenase-2 expressed hepatocellular carcinoma induces cytotoxic T lymphocytes exhaustion through M2 macrophage polarization. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 4360-4375.	0.0	5
668	Clinical determinants of relapse following CAR-T therapy for hematologic malignancies: Coupling active strategies to overcome therapeutic limitations. <i>Current Research in Translational Medicine</i> , 2022, 70, 103320.	1.2	9
669	T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas. <i>Clinical Cancer Research</i> , 2022, 28, 378-389.	3.2	11
670	Immunotherapy Approaches in HPV-Associated Head and Neck Cancer. <i>Cancers</i> , 2021, 13, 5889.	1.7	21
671	Tailoring Aggregation Extent of Photosensitizers to Boost Phototherapy Potency for Eliciting Systemic Antitumor Immunity. <i>Advanced Materials</i> , 2022, 34, e2106390.	11.1	65

#	ARTICLE	IF	CITATIONS
672	AssociaÃ§Ã£o Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VII. Present and future of technologies for production of CAR cell therapies. Hematology, Transfusion and Cell Therapy, 2021, 43, S46-S53.	0.1	0
673	Targeting HLA-DR loss in hematologic malignancies with an inhibitory chimeric antigen receptor. Molecular Therapy, 2022, 30, 1215-1226.	3.7	9
675	Using chimeric antigen receptor T-cell therapy to fight glioblastoma multiforme: past, present and future developments. Journal of Neuro-Oncology, 2022, 156, 81-96.	1.4	9
676	Injectable and Biodegradable Chitosan Hydrogel-Based Drug Depot Contributes to Synergistic Treatment of Tumors. Biomacromolecules, 2021, 22, 5339-5348.	2.6	17
677	Predicting T cell quality during manufacturing through an artificial intelligence-based integrative multiomics analytical platform. Bioengineering and Translational Medicine, 2022, 7, e10282.	3.9	9
678	Metabolic installation of macrophage-recruiting glycan ligand on tumor cell surface for in vivo tumor suppression. Bioorganic and Medicinal Chemistry Letters, 2022, 57, 128500.	1.0	1
679	Therapeutic efficacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models. Neoplasia, 2022, 24, 98-108.	2.3	6
680	Fundamentals to clinical application of nanoparticles in cancer immunotherapy and radiotherapy. Ecancermedicalscience, 2020, 14, 1095.	0.6	5
682	Semaphorins as Potential Immune Therapeutic Targets for Cancer. Frontiers in Oncology, 2022, 12, 793805.	1.3	3
683	Targeting Protein Tyrosine Phosphatase 22 Does Not Enhance the Efficacy of Chimeric Antigen Receptor T Cells in Solid Tumors. Molecular and Cellular Biology, 2022, 42, MCB0044921.	1.1	8
684	Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia. Cancers, 2022, 14, 497.	1.7	17
685	Impact of Cancer Stem Cells and Cancer Stem Cell-Driven Drug Resiliency in Lung Tumor: Options in Sight. Cancers, 2022, 14, 267.	1.7	11
686	Emerging strategies for biomaterial-assisted cancer immunotherapy. Korean Journal of Chemical Engineering, 2022, 39, 227-240.	1.2	1
687	TCR-T Immunotherapy: The Challenges and Solutions. Frontiers in Oncology, 2021, 11, 794183.	1.3	36
688			

#	ARTICLE	IF	CITATIONS
692	Motif-dependent immune co-receptor interactome profiling by photoaffinity chemical proteomics. <i>Cell Chemical Biology</i> , 2022, 29, 1024-1036.e5.	2.5	8
694	IL-13R α 2 humanized scFv-based CAR-T cells exhibit therapeutic activity against glioblastoma. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 443-451.	2.0	8
696	Multifunctional theranostic nanoparticles for multi-modal imaging-guided CAR-T immunotherapy and chemo-photothermal combinational therapy of non-Hodgkin's lymphoma. <i>Biomaterials Science</i> , 2022, 10, 2577-2589.	2.6	10
697	A Costimulatory CAR Improves TCR-based Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2022, 10, 512-524.	1.6	12
698	Research Progress in Alpha-fetoprotein-induced Immunosuppression of Liver Cancer. <i>Mini-Reviews in Medicinal Chemistry</i> , 2022, 22, 2237-2243.	1.1	12
699	Emerging CAR T Cell Strategies for the Treatment of AML. <i>Cancers</i> , 2022, 14, 1241.	1.7	24
700	Site-Specific Dinitrophenylation of Single-Chain Antibody Fragments for Redirecting a Universal CAR-T Cell against Cancer Antigens. <i>Journal of Molecular Biology</i> , 2022, 434, 167513.	2.0	6
701	Harnessing the Anti-Tumor Mediators in Mast Cells as a New Strategy for Adoptive Cell Transfer for Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 830199.	1.3	9
703	Development of a Localized Drug Delivery System with a Step-by-Step Cell Internalization Capacity for Cancer Immunotherapy. <i>ACS Nano</i> , 2022, 16, 5778-5794.	7.3	18
704	Recent Advances in CAR T-Cell Therapy for Patients with Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2022, 14, 1715.	1.7	9
705	Update for Advance CAR-T Therapy in Solid Tumors, Clinical Application in Peritoneal Carcinomatosis From Colorectal Cancer and Future Prospects. <i>Frontiers in Immunology</i> , 2022, 13, 841425.	2.2	10
706	Tuning T cell receptor sensitivity through catch bond engineering. <i>Science</i> , 2022, 376, eabl5282.	6.0	53
707	Cellular immunotherapy in gastric cancer: adoptive cell therapy and dendritic cell-based vaccination. <i>Immunotherapy</i> , 2022, 14, 475-488.	1.0	12
708	Cell Trafficking at the Intersection of the Tumor and Immune Compartments. <i>Annual Review of Biomedical Engineering</i> , 2022, 24, 275-305.	5.7	9
709	IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma. <i>Cancer Letters</i> , 2022, 536, 215663.	3.2	1
710	A Comprehensive Review of Recent Advancements in Cancer Immunotherapy and Generation of CAR T Cell by CRISPR-Cas9. <i>Processes</i> , 2022, 10, 16.	1.3	13
732	New approaches in chimeric antigen receptor T-cell therapy for breast cancer. <i>Journal of Central South University (Medical Sciences)</i> , 2020, 45, 1120-1126.	0.1	0
735	Cytokine Release Syndrome After Modified CAR-NK Therapy in an Advanced Non-small Cell Lung Cancer Patient: A Case Report. <i>Cell Transplantation</i> , 2022, 31, 096368972210942.	1.2	13

#	ARTICLE	IF	CITATIONS
736	Advances in Chimeric Antigen Receptor (CAR) T-Cell Therapies for the Treatment of Primary Brain Tumors. <i>Antibodies</i> , 2022, 11, 31.	1.2	4
737	Cell surface-tethered IL-12 repolarizes the tumor immune microenvironment to enhance the efficacy of adoptive T cell therapy. <i>Science Advances</i> , 2022, 8, eabi8075.	4.7	21
738	Engineered bacterial membrane vesicles are promising carriers for vaccine design and tumor immunotherapy. <i>Advanced Drug Delivery Reviews</i> , 2022, 186, 114321.	6.6	36
739	Enhanced human T cell expansion with inverse opal hydrogels. <i>Biomaterials Science</i> , 2022, 10, 3730-3738.	2.6	9
740	PTPN22: structure, function, and developments in inhibitor discovery with applications for immunotherapy. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 825-837.	2.5	3
741	Nanodrugs Targeting T Cells in Tumor Therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
742	Bidirectional effects of intestinal microbiota and antibiotics: a new strategy for colorectal cancer treatment and prevention. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2387-2404.	1.2	6
743	Tailoring Multifunctional Small Molecular Photosensitizers to In Vivo Self-Assemble with Albumin to Boost Tumor-Preferential Accumulation, NIR Imaging, and Photodynamic/Photothermal/Immunotherapy. <i>Small</i> , 2022, 18, .	5.2	11
744	Bioengineered nanogels for cancer immunotherapy. <i>Chemical Society Reviews</i> , 2022, 51, 5136-5174.	18.7	81
745	Synergistic Therapeutic Effects of Low Dose Decitabine and NY-ESO-1 Specific TCR-T Cells for the Colorectal Cancer With Microsatellite Stability. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
746	Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 529-540.	21.5	134
748	Tumor immunotherapy: Mechanisms and clinical applications. , 2022, 1, .		2
749	From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer. <i>Journal of Inflammation Research</i> , 0, Volume 15, 4061-4085.	1.6	1
750	Case Report: Clinical and Serological Hallmarks of Cytokine Release Syndrome in a Canine B Cell Lymphoma Patient Treated With Autologous CAR-T Cells. <i>Frontiers in Veterinary Science</i> , 0, 9, .	0.9	4
751	Advances and challenges of CAR-T therapy and suitability of animal models (Review). <i>Molecular and Clinical Oncology</i> , 2022, 17, .	0.4	4
752	Current landscape of gene editing technology in biomedicine: Applications, advantages, challenges, and perspectives. <i>MedComm</i> , 2022, 3, .	3.1	2
753	Multivalent, Bispecific B7-H3-CD3 Chemically Self-Assembled Nanorings Direct Potent T Cell Responses against Medulloblastoma. <i>ACS Nano</i> , 2022, 16, 12185-12201.	7.3	6
754	Pancreatic tumor eradication via selective Pin1 inhibition in cancer-associated fibroblasts and T lymphocytes engagement. <i>Nature Communications</i> , 2022, 13, .	5.8	14

#	ARTICLE	IF	CITATIONS
756	DLL4 and VCAM1 enhance the emergence of T cellâ€‘competent hematopoietic progenitors from human pluripotent stem cells. <i>Science Advances</i> , 2022, 8, .	4.7	15
757	Unified Therapeuticâ€‘Prophylactic Vaccine Demonstrated with a Postoperative Filler Gel to Prevent Tumor Recurrence and Metastasis. <i>Advanced Functional Materials</i> , 2022, 32, .	7.8	17
758	<scp>DLK1</scp>â€‘directed chimeric antigen receptor Tâ€‘cell therapy for hepatocellular carcinoma. <i>Liver International</i> , 2022, 42, 2524-2537.	1.9	4
759	EZH1 repression generates mature iPSC-derived CAR Tâ€‘cells with enhanced antitumor activity. <i>Cell Stem Cell</i> , 2022, 29, 1181-1196.e6.	5.2	36
760	The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes. <i>Blood Advances</i> , 2022, 6, 6040-6050.	2.5	8
761	Emerging immune-based technologies for high-grade gliomas. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 957-980.	1.1	1
762	Intracavity generation of glioma stem cellâ€‘specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	68
763	RASA2 ablation in T cells boosts antigen sensitivity and long-term function. <i>Nature</i> , 2022, 609, 174-182.	13.7	65
764	Methylation related genes are associated with prognosis of patients with head and neck squamous cell carcinoma via altering tumor immune microenvironment. <i>Journal of Dental Sciences</i> , 2022, , .	1.2	2
765	Melanoma-derived small extracellular vesicles remodel the systemic onco-immunity via disrupting hematopoietic stem cell proliferation and differentiation. <i>Cancer Letters</i> , 2022, 545, 215841.	3.2	7
766	Exploration of the underlying biological differences and targets in ovarian cancer patients with diverse immunotherapy response. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
767	Nano-drug delivery systems for T cell-based immunotherapy. <i>Nano Today</i> , 2022, 46, 101621.	6.2	13
768	Potency monitoring of CAR T cells. <i>Methods in Cell Biology</i> , 2023, , 173-189.	0.5	1
769	Targeting Metastatic Disease: Challenges and New Opportunities. , 2022, , 51-68.		0
770	The Bibliometric Landscape of Gene Editing Innovation and Regulation in the Worldwide. <i>Cells</i> , 2022, 11, 2682.	1.8	18
771	Co-expression IL-15 receptor alpha with IL-15 reduces toxicity via limiting IL-15 systemic exposure during CAR-T immunotherapy. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	10
772	A novel LUAD prognosis prediction model based on immune checkpoint-related lncRNAs. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
773	Systematic panâ€‘cancer analysis identifies CDC45 as having an oncogenic role in human cancers. <i>Oncology Reports</i> , 2022, 48, .	1.2	4

#	ARTICLE	IF	CITATIONS
774	Novel cellular therapies for hepatobiliary malignancies. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, , .	0.6	1
776	The T Cell Journey: A Tour de Force. <i>Advanced Biology</i> , 2023, 7, .	1.4	4
777	ç»†èƒžèì“éçâ¥ç“çš,,ç–ç•¥âšâ”ç”“. <i>Scientia Sinica Vitae</i> , 2022, , .	0.1	0
779	Anti-Apoptotic c-FLIP Reduces the Anti-Tumour Activity of Chimeric Antigen Receptor T Cells. <i>Cancers</i> , 2022, 14, 4854.	1.7	1
781	Tumor microenvironment: barrier or opportunity towards effective cancer therapy. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	67
782	Biomimetic cell membraneâ€œcoated poly(lacticâ€œ<sc><i>co</i></sc>â€œglycolic acid) nanoparticles for biomedical applications. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	3.9	25
783	Targeted Therapy and Immunotherapy for Heterogeneous Breast Cancer. <i>Cancers</i> , 2022, 14, 5456.	1.7	8
784	Advances of Electroporation-Related Therapies and the Synergy with Immunotherapy in Cancer Treatment. <i>Vaccines</i> , 2022, 10, 1942.	2.1	7
785	Prognostic and therapeutic prediction by screening signature combinations from transcriptomeâ€œmethylome interactions in oral squamous cell carcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
786	Cellâ€œBased Drug Delivery Systems Participate in the Cancer Immunity Cycle for Improved Cancer Immunotherapy. <i>Small</i> , 2023, 19, .	5.2	10
787	DNA origamiâ€œbased artificial antigen-presenting cells for adoptive T cell therapy. <i>Science Advances</i> , 2022, 8, .	4.7	17
788	Disruption of CISH promotes the antitumor activity of human Tâ€œcells and decreases PD-1 expression levels. <i>Molecular Therapy - Oncolytics</i> , 2023, 28, 46-58.	2.0	7
789	Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 2709-2734.	1.2	6
790	Role of T cells in cancer immunotherapy: Opportunities and challenges. , 2023, 1, 116-126.		11
791	Modifying enzyme replacement therapy â€œ A perspective. <i>Journal of Cellular and Molecular Medicine</i> , 2023, 27, 165-173.	1.6	6
793	Mapping the interplay between NK cells and HIV: therapeutic implications. <i>Journal of Leukocyte Biology</i> , 2023, 113, 109-138.	1.5	1
794	Engineered bacteria for augmented<i>in situ</i> tumor vaccination. <i>Biomaterials Science</i> , 2023, 11, 1137-1152.	2.6	6
795	Chimeric antigen receptor T (<sc>CARâ€œ</sc>) cells: Novel cell therapy for hematological malignancies. <i>Cancer Medicine</i> , 2023, 12, 7844-7858.	1.3	15

#	ARTICLE	IF	CITATIONS
796	Advances in adoptive cellular therapy for colorectal cancer: a narrative review. <i>Annals of Translational Medicine</i> , 2022, 10, 1404-1404.	0.7	4
797	CAR T cells: engineered immune cells to treat brain cancers and beyond. <i>Molecular Cancer</i> , 2023, 22, .	7.9	7
798	Analysis of causes for poor persistence of CAR-T cell therapy in vivo. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
799	Developments of PROTACs technology in immune-related diseases. <i>European Journal of Medicinal Chemistry</i> , 2023, 249, 115127.	2.6	4
800	CAR-T cells for cancer immunotherapy. <i>Chinese Chemical Letters</i> , 2023, 34, 108202.	4.8	3
801	Improving the sensitivity of in vivo CRISPR off-target detection with DISCOVER-Seq+. <i>Nature Methods</i> , 2023, 20, 706-713.	9.0	5
802	Capsid-modified adeno-associated virus vectors as novel vaccine platform for cancer immunotherapy. <i>Molecular Therapy - Methods and Clinical Development</i> , 2023, 29, 238-253.	1.8	1
804	The research status and prospects of MUC1 in immunology. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	3
806	Targeting fibroblast activation protein (FAP): advances in CAR-T cell, antibody, and vaccine in cancer immunotherapy. <i>Drug Delivery and Translational Research</i> , 2023, 13, 2041-2056.	3.0	9
808	The Role of Different Immunocompetent Cell Populations in the Pathogenesis of Head and Neck Cancer—Regulatory Mechanisms of Pro- and Anti-Cancer Activity and Their Impact on Immunotherapy. <i>Cancers</i> , 2023, 15, 1642.	1.7	4
809	CAR T Cell Therapy: A Versatile Living Drug. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6300.	1.8	10
810	Biofunctionalized 3D printed structures for biomedical applications: A critical review of recent advances and future prospects. <i>Progress in Materials Science</i> , 2023, 137, 101124.	16.0	6
811	Engineering a modular double-transmembrane synthetic receptor system for customizing cellular programs. <i>Cell Reports</i> , 2023, 42, 112385.	2.9	5
812	Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma post-liver transplantation: results from a phase I trial. <i>Hepatology International</i> , 2023, 17, 850-859.	1.9	2
813	Modern T cell technologies for immunotherapy of solid tumors. <i>Medical Immunology (Russia)</i> , 2023, 25, 271-286.	0.1	0
833	Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2023, 71, .	1.0	1
842	Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy. , 2023, 40, .		3
843	Emerging Vaccine for the Treatment of Cancer Via Nanotechnology. , 2023, , 79-99.		0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------